AO 120 (Rev. 3/04)

TO:	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court District of Massachusetts on the following ✓ Patents or Trademarks:

DOCKET NO.	DATE FILED	U.S. DISTRICT COURT
	5/25/2021	District of Massachusetts

PLAINTIFF	DEFENDANT
MILLIMAN, INC., MILLIMAN SOLUTIONS, LLC, and VIGILYTICS LLC	GRADIENT A.I. CORP., STANFORD A. SMITH, and SAMUEL CHASE PETTUS

	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	SEE ATTACHED		
2			
3			
4			
5			

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY: Amendment / Answer / Cross Bill / Other Pleading		
	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE

Copy 1—Upon initiation of action, mail this copy to Director **Copy 3—Upon termination of action, mail this copy to Director**
Copy 2—Upon filing document adding patent(s), mail this copy to Director **Copy 4—Case file copy**

AO 120 - ATTACHMENT PAGE

	PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1	U.S. Patent No. 9,118,641	Aug. 25, 2015	Vigilytics LLC
2	U.S. Patent No. 9,323,892	Apr. 26, 2016	Vigilytics LLC
3	U.S. Patent No. 9,665,685	May 30, 2017	Vigilytics LLC
4	U.S. Patent No. 9,965,651	May 8, 2018	Vigilytics LLC
5	U.S. Patent No. 10,109,375	Oct. 23, 2018	Vigilytics LLC
6	U.S. Patent No. 10,886,012	Jan. 5, 2021	Vigilytics LLC

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY.DOCKET NO./TITLE	REQUEST ID
12/827,745	06/30/2010	Andrew L. Paris	25412-0002001	77149

Acknowledgement of Loss of Entitlement to Entity Status Discount

The entity status change request below filed through Private PAIR on 12/10/2018 has been accepted.

CERTIFICATIONS:

Change of Entity Status:

X Applicant changing to regular undiscounted fee status.

NOTE: Checking this box will be taken to be notification of loss of entitlement to small or micro entity status, as applicable.

This portion must be completed by the signatory or signatories making the entity status change in accordance with 37 CFR 1.4(d)(4).

Signature:	/Jeffrey J. Barclay, Reg. No. 48,950/
Name:	Jeffrey J. Barclay
Registration Number:	48950

Electronic Acknowledgement Receipt	
EFS ID:	22550564
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	05-JUN-2015
Filing Date:	30-JUN-2010
Time Stamp:	14:39:25
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$920
RAM confirmation Number	881
Deposit Account	061050
Authorized User	FISH & RICHARDSON P C
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Petition Fee-37CFR 1.17(h) (Group II)	2464	1	70	70
RCE- 2nd and Subsequent Request	2820	1	850	850
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				

Adjustment date: 05/01/2017 SDARETA1 12827745
08/c015 INTERSW 00000001 661050
850.00 CR
02 FC:2820

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	08/25/2015	9118641	25412-0002001	5602

26161 7590 08/05/2015

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 242 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Andrew L. Paris III, Victor, NY;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 07/24/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
07/24/2015	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Notice of Allowability	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *06/05/2015*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *28-46*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____.
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date *01/28/2015*.
5. ☐ Examiner's Amendment/Comment
6. ☐ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2007/0219824	09/2007	Rawlings et al			
	2	2008/0010254	01/2008	Settimi			
	3	2008/0120296	05/2008	Kariathungal et al.			
	4						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	5							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	6	

Examiner Signature	Date Considered
/Evans Desrosiers/	07/15/2015

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form

ALL REFERENCES CONSIDERED EXCEPT WHERE INDICATED /E.D./

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

PATENT WITHDRAWAL NOTICE

DATE WITHDRAWN	WITHDRAWAL NUMBER
6/9/2015	29302

The following application has been **WITHDRAWN** from the

6/9/2015 issue.

SERIAL NO.	PATENT NUMBER
12827745	9055049

TITLE

DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

NAME AND ADDRESS

ANDREW PARIS
Victor, NY

REASON FOR WITHDRAWAL

Auto-petition to withdraw - Granted
-

APPROVED

/Kimberly Terrell/, Manager

Patent Publication Branch
Office of Data Management

FORM PTO-302 -- (REV. 05-2009)

PTO/SB/30 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	12/827,745
Filing Date	June 30, 2010
First Named Inventor	Andrew L. Paris III
Art Unit	2491
Examiner Name	Evans Desrosiers
Attorney Docket Number	25412-0002001

This is a Request for Continued Examination (RCE) under 37 CFR 1 .114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

ii. ☐ Other _____

b. ☒ Enclosed

i. ☐ Amendment/Reply

iii. ☒ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/ Declaration(s)

iv. ☒ Other Certification and Request for Consideration of an Information Disclosure Statement Filed After Payment of the Issue Fee Under the QPIDS Pilot Program

2. Miscellaneous

Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

a. ☐ period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other _____

3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
The Director is hereby authorized to charge the following fees any underpayment of fees or credit any overpayments to

a. ☒ Deposit Account No. 06-1050 .

i. ☒ RCE fee required under 37 CFR 1.17(e)

ii ☐ Extension of time fee (37 CFR 1.136 and 1.17)

iii ☒ Other any deficiencies

b. ☐ Check in the amount of $ _____ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/	Date	5 June 2015
Name (Print/Type)	Jeffrey J. Barclay	Registration No.	48,950

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature			
Name (Print/Type)		Date	

American LegalNet, Inc.
www.FormsWorkFlow.com

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkFlow.com

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Petition Fee-37CFR 1.17(h) (Group II)	2464	1	70	70
RCE- 2nd and Subsequent Request	2820	1	850	850
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**920**

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Decision Date : June 5, 2015

In re Application of :

Andrew Paris

DECISION ON PETITION

UNDER CFR 1.313(c)(2)

Application No : 12827745

Filed : 30-Jun-2010

Attorney Docket No : 25412-0002001

This is an electronic decision on the petition under 37 CFR 1.313(c)(2), filed June 5, 2015 , to withdraw the above-identified application from issue after payment of the issue fee.

The petition is **GRANTED.**

The above-identified application is withdrawn from issue for consideration of a submission under 37 CFR 1.114 (request for continued examination). See 37 CFR 1.313(c)(2).

Petitioner is advised that the issue fee paid in this application cannot be refunded. If, however, this application is again allowed, petitioner may request that it be applied towards the issue fee required by the new Notice of Allowance.

Telephone inquiries concerning this decision should be directed to the Patent Electronic Business Center (EBC) at 866-217-9197.

This application file is being referred to Technology Center AU 2491 for processing of the request for continuing examination under 37 CFR 1.114 .

Office of Petitions

Electronic Acknowledgement Receipt

EFS ID:	22550564
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	05-JUN-2015
Filing Date:	30-JUN-2010
Time Stamp:	14:39:25
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$920
RAM confirmation Number	881
Deposit Account	061050
Authorized User	FISH & RICHARDSON P C

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Petition automatically granted by EFS	petition-request.pdf	31465 5bb3d92824966c041501d1958bdc4e80993d73b0	no	2
Warnings:					
Information:					
2		IDS.pdf	122714 a9af30bb1f3fdc7291703b471688097ec8ae7151	yes	3

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	2
	Information Disclosure Statement (IDS) Form (SB08)	3	3

Warnings:					
Information:					
3	Request for Continued Examination (RCE)	RCE.pdf	108664 2bb78a324642a67625aeae2494bfca1d9338dd75	no	2
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
4	Quick Path Information Disclosure Statement	QPIDS.pdf	157428 040e3d4b6707a795a151b3c72b9a2487cb7a2ebb	no	2
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	32382 ea2836abde46524ac3d62412794ceaa0d7e11e5a	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	452653		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: PET.AUTO Document Description: Petition automatically granted by EFS-Web	PTO/SB/140 U.S. Patent and Trademark Office Department of Commerce

Electronic Petition Request	**PETITION TO WITHDRAW AN APPLICATION FROM ISSUE AFTER PAYMENT OF THE ISSUE FEE UNDER 37 CFR 1.313(c)**
Application Number	12827745
Filing Date	30-Jun-2010
First Named Inventor	Andrew Paris
Art Unit	2491
Examiner Name	EVANS DESROSIERS
Attorney Docket Number	25412-0002001
Title	De-identifying Medical History Information for Medical Underwriting

An application may be withdrawn from issue for further action upon petition by the applicant. To request that the Office withdraw an application from issue, applicant must file a petition under this section including the fee set forth in § 1.17(h) and a showing of good and sufficient reasons why withdrawal of the application from issue is necessary.

APPLICANT HEREBY PETITIONS TO WITHDRAW THIS APPLICATION FROM ISSUE UNDER 37 CFR 1.313(c).

A grantable petition requires the following items:
(1) Petition fee; and
(2) One of the following reasons:
(a) Unpatentability of one or more claims, which must be accompanied by an unequivocal statement that one or more claims are unpatentable, an amendment to such claim or claims, and an explanation as to how the amendment causes such claim or claims to be patentable;
(b) Consideration of a request for continued examination in compliance with § 1.114 (for a utility or plant application only); or
(c) Express abandonment of the application. Such express abandonment may be in favor of a continuing application, but not a CPA under 37 CFR 1.53(d).

Petition Fee

◉	Small Entity
○	Micro Entity
○	Regular Undiscounted

Reason for withdrawal from issue

◯ One or more claims are unpatentable ◉ Consideration of a request for continued examination (RCE) (List of Required Documents and Fees) ◯ Applicant hereby expressly abandons the instant application (any attorney/agent signing for this reason must have power of attorney pursuant to 37 CFR 1.32(b)).
RCE request,submission, and fee. ☐ I certify, in accordance with 37 CFR 1.4(d)(4) that : The RCE request ,submission, and fee have already been filed in the above-identified application on ☒ Are attached.
THIS PORTION MUST BE COMPLETED BY THE SIGNATORY OR SIGNATORIES I certify, in accordance with 37 CFR 1.4(d)(4) that I am: ◉ An attorney or agent registered to practice before the Patent and Trademark Office who has been given power of attorney in this application. ◯ An attorney or agent registered to practice before the Patent and Trademark Office, acting in a representative capacity. ◯ A sole inventor ◯ A joint inventor; I certify that I am authorized to sign this submission on behalf of all of the inventors as evidenced by the power of attorney in the application ◯ A joint inventor; all of whom are signing this e-petition

Signature	/Jeffrey J. Barclay/
Name	Jeffrey J. Barclay
Registration Number	48950

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Patent No.	:	9,055,049	Examiner	:	Evans Desrosiers
Issue Date	:	June 9, 2015	Conf. No.	:	5602
Serial No.	:	12/827,745			
Filed	:	June 30, 2010			
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This Information Disclosure Statement is being submitted through the Quick Path Information Disclosure Statement Pilot Program. This art was recently cited on June 3, 2015 in related U.S. application 14/082,433.

This filing is being made along with the filing of a conditional Request for Continued Examination, PTO Form SB09 (Certification and Request for Consideration of an Information Disclosure Statement Filed After Payment of the Issue Fee Under the QPIDS Pilot Program), and a Web-based ePetition to Withdraw from Issue After Payment of the Issue Fee with Assigned Patent Number.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 5 June 2015

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23400817.doc

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2007/0219824	09/2007	Rawlings et al			
	2	2008/0010254	01/2008	Settimi			
	3	2008/0120296	05/2008	Kariathungal et al.			
	4						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	5							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	6	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 07/08/2015

THARGROV	SALE	#00000002	Mailroom Dt:	06/05/2015	061050	12827745
	01	FC : 2806		90.00 DA		

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/09/2015	9055049	25412-0002001	5602

26161 7590 05/20/2015

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 241 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

Andrew L. Paris III, Victor, NY;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The Applicants appreciate and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application in phones calls between 28 January 2015 and 3 February 2015 with the Applicants' representative, Jeffrey J. Barclay (Reg. No. 48,950). Along with discussing the current action, the pending claims were also discussed. The Applicants would also like to thank Examiner Desrosiers for agreeing to review claim amendments respectively provided by the undersigned via corresponding electronic mail messages. Attached is the e-mail of January 30, 2015 sent from Applicants' representative to the Examiner with a first Applicant-proposed amendment, an email with the Examiner's proposed first amendment sent January 31, 2015, and Applicant's representative's response to same on February 1, 2015. Also included is a second Applicant-proposed amendment and email sent February 3, 2015 and a third Applicant-proposed amendment also sent February 3, 2015.

Respectfully submitted,

Date: 6 May 2015

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23355041.doc

Appendix A

January 30, 2015 e-mail: Applicant's Representative to Examiner

From: Jeffrey Barclay
Sent: Thursday, January 29, 2015 4:00 PM
To: 'evans.desrosiers@uspto.gov'
Cc: Jeffrey Barclay
Subject: Proposed claim amendment for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thank you again for our telephone conversation yesterday.

Please find attached one MS-Word document that contains proposed claims amendments we discussed.
I will call you to discuss these amendments and the application in general.

Of course, please feel free to call me at any time.

Thanks again for your time in this matter,

Jeff

Jeffrey Barclay :: Principal

Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

Proposed claim amendments for Application No. 12/827,745

1. (Currently Amended) A computer-implemented method comprising:

in response to a request for information, producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein producing the information includes producing a request token for each individual included in the group, comparing the request tokens to tokens associated with the information to be produced, the tokens associated with the information to be produced and the request tokens being similarly encrypted, the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor, unique identifiers, wherein the identity of the individuals in the group is unattainable from the unique identifiers, each unique identifier being associated with a corresponding unique identifier in a set of de-identified healthcare data, and each unique identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing the requested healthcare information that characterizes the group by identifying the unique identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced unique identifiers, wherein the produced unique identifiers and the unique identifiers in the set of de-identified healthcare data are similarly encrypted, wherein the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

Appendix B

January 31, 2015 e-mail: Examiner to Applicant's Representative

From: Desrosiers, Evans [mailto:evans.desrosiers@USPTO.GOV]
Sent: Saturday, January 31, 2015 1:52 PM
To: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Hi Jeffrey,

Please find attached the amendment which is from the specification paragraph [0022], if you agree please let me know. Also, there is an obviousness double patenting for No. 14/080,433.

Thank you,

Evans Desrosiers
Primary Patent Examiner
U.S. Patent & Trademark Office
500 Dulany St. Office 9D31
(571) 270-5438
Fax (571) 270-6438
Evans.Desrosiers@uspto.gov

Proposed claim set for Application No. 12/827,745

1. – 27. (Cancelled)

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

wherein the request healthcare information is sent to an encryption server, when the request healthcare information contains a minimum number of group individuals, the encryption server creates a unique token for each person in the healthcare information that encrypts the personally identifiable information of each group individual,

producing, by a processor, ~~unique identifiers~~ tokens, wherein the identity of the individuals in the group is unattainable from the ~~unique identifiers~~ tokens, each ~~unique identifier~~ token being associated with a corresponding ~~unique identifier~~ token in a set of de-identified healthcare data, and each ~~unique identifier~~ token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing the requested healthcare information that characterizes the group by identifying the ~~unique identifiers~~ tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced ~~unique identifiers~~ tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

31. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

32. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

33. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

34. (New) The computer-implemented method of claim 28, in which the healthcare data represents medical related information associated with the individuals of the group.

35. (New) A system including a server with a processor and a memory, comprising:

an encryption server for producing a token for each individual included in a group composed of multiple individuals identified in a request for healthcare information that characterizes the group, wherein the identity of the individuals in the group is

unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

a data server for producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

36. (New) The system of claim 35, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

37. (New) The system of claim 35, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

38. (New) The system of claim 35, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

39. (New) The system of claim 35, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

40. (New) The system of claim 35, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

41. (New) The system of claim 35, in which the healthcare data represents medical related information associated with the individuals of the group.

42. (New) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

wherein the request healthcare information is sent to an encryption server, when the request healthcare information contains a minimum number of group individuals, the encryption server creates a unique token for each person in the healthcare information that encrypts the personally identifiable information of each group individual,

producing, by a processor, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

43. (New) The computer readable storage devices of claim 42, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

44. (New) The computer readable storage devices of claim 42, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

45. (New) The computer readable storage devices of claim 42, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

46. (New) The computer readable storage devices of claim 42, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

47. (New) The computer readable storage devices of claim 42, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

48. (New) The computer readable storage devices of claim 42, in which the healthcare data represents medical related information associated with the individuals of the group.

Appendix C

February 1, 2015 e-mail: Applicant's Representative to Examiner

From: Jeffrey Barclay
Sent: Sunday, February 01, 2015 4:53 PM
To: 'Desrosiers, Evans'
Cc: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thanks for your message, and the attachment.

I'll call you tomorrow morning and we can talk through your comments.

Thanks again, and looking forward to our discussion,

Jeff

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

Appendix D

February 3, 2015 e-mail: Applicant's Representative to Examiner

From: Jeffrey Barclay
Sent: Tuesday, February 03, 2015 11:44 AM
To: Desrosiers, Evans
Cc: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thank you again for our telephone call yesterday.

The applicant and I were able to have a telephone conversation this morning and discuss the claims.
Please find attached one MS-Word document that contains a proposed claim set based on your message (below).
Please feel free to call me at any time. I'll also call you right now.

Thanks again for your time in this matter,

Jeff

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

Proposed amended claim set for Application No. 12/827,745

1. – 27. (Cancelled)

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, ~~unique identifiers~~ tokens, wherein the identity of the individuals in the group is unattainable from the ~~unique identifiers~~ tokens, each token being associated with an individual in the group, each ~~unique identifier~~ token being associated with a corresponding ~~unique identifier~~ token in a set of de-identified healthcare data, and each ~~unique identifier~~ token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

if the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the ~~unique identifiers~~ tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced ~~unique identifiers~~ tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

31. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

32. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

33. (New) The computer-implemented method of claim 28, in which the healthcare data represents medical related information associated with the individuals of the group.

34. (New) A system comprising:

an encryption server, having a processor and a memory, for producing a token for each individual included in a group composed of multiple individuals identified in a request for healthcare information that characterizes the group, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

a data server for producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

35. (New) The system of claim 34, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

36. (New) The system of claim 34, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

37. (New) The system of claim 34, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

38. (New) The system of claim 34, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

39. (New) The system of claim 34, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

40. (New) The system of claim 34, in which the healthcare data represents medical related information associated with the individuals of the group.

41. (New) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token

in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

if the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

42. (New) The computer readable storage devices of claim 41, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

43. (New) The computer readable storage devices of claim 41, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

44. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

45. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

46. (New) The computer readable storage devices of claim 41, in which the healthcare data represents medical related information associated with the individuals of the group.

23349488.doc

Datavant Exhibit 1002
Page 46 of 468

Appendix E

February 3, 2015 e-mail: Applicant's Representative to Examiner

From: Jeffrey Barclay
Sent: Tuesday, February 03, 2015 2:42 PM
To: Desrosiers, Evans
Cc: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thank you again for the telephone call today.

As we discussed, the claim amendments have been adjusted as we discussed.
Please find attached one MS-Word document that contains the adjusted claim set. This is the second set of claims that has been sent to you today, 3 February 2015.
Please feel free to call me at any time. I'll also call you right now.

Thanks again for your time in this matter,

Jeff

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

Proposed amended claim set for Application No. 12/827,745
(Second set – sent 3 February 2015)

1. – 27. (Cancelled)

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, ~~unique identifiers~~ tokens, wherein the identity of the individuals in the group is unattainable from the ~~unique identifiers~~ tokens, each token being associated with an individual in the group, each ~~unique identifier~~ token being associated with a corresponding ~~unique identifier~~ token in a set of de-identified healthcare data, and each ~~unique identifier~~ token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the ~~unique identifiers~~ tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced ~~unique identifiers~~ tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

31. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

32. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

33. (New) The computer-implemented method of claim 28, in which the healthcare data represents medical related information associated with the individuals of the group.

34. (New) A system comprising:

an encryption server, having a processor and a memory, for producing a token for each individual included in a group composed of multiple individuals identified in a request for healthcare information that characterizes the group, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

a data server for producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

35. (New) The system of claim 34, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

36. (New) The system of claim 34, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

37. (New) The system of claim 34, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

38. (New) The system of claim 34, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

39. (New) The system of claim 34, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

40. (New) The system of claim 34, in which the healthcare data represents medical related information associated with the individuals of the group.

41. (New) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token

in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

42. (New) The computer readable storage devices of claim 41, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

43. (New) The computer readable storage devices of claim 41, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

44. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

45. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

46. (New) The computer readable storage devices of claim 41, in which the healthcare data represents medical related information associated with the individuals of the group.

23349488.doc

Datavant Exhibit 1002
Page 53 of 468

Electronic Acknowledgement Receipt

EFS ID:	22266178
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Alyssa Broderick
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	06-MAY-2015
Filing Date:	30-JUN-2010
Time Stamp:	09:43:10
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Applicant summary of interview with examiner	Interview_Summary.pdf	553741 fd6c0b9f1eb666d6b66528fc1d356bed6103e3d6	no	28

Warnings:	
Information:	

Total Files Size (in bytes):	553741

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 04/24/2015

FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

TITLE OF INVENTION: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$480	$0	$0	$480	07/24/2015

EXAMINER	ART UNIT	CLASS-SUBCLASS
DESROSIERS, EVANS	2491	713-168000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

[ ] Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

[ ] "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

1 Fish & Richardson P.C.

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE
Vigilytics LLC

(B) RESIDENCE: (CITY and STATE OR COUNTRY)
Victor, New York

Please check the appropriate assignee category or categories (will not be printed on the patent): **[ ]** Individual [X] Corporation or other private group entity [ ] Government

4a. The following fee(s) are submitted:

[X] Issue Fee

[ ] Publication Fee (No small entity discount permitted)

[ ] Advance Order - # of Copies _____

4b. Payment of Fee(s): (**Please first reapply any previously paid issue fee shown above**)

[ ] A check in the amount of the fee(s) is enclosed.

[ ] Payment by credit card. Form PTO-2038 is attached.

[X] The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050

5. **Change in Entity Status** (from status indicated above)

[ ] Applicant certifying micro entity status. See 37 CFR 1.29 — **NOTE**: Absent a valid certification of Micro Entity Status (see form PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

[ ] Applicant asserting small entity status. See 37 CFR 1.27. — **NOTE**: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

[ ] Applicant changing to regular undiscounted fee status. — **NOTE**: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.
NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature /Jeffrey J. Barclay, Reg. No. 48,950/ Date 29 April 2015

Typed or printed name Jeffrey J. Barclay Registration No. 48,950

23386098.doc

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Utility Appl Issue Fee	2501	1	480	480

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**480**

Electronic Acknowledgement Receipt

EFS ID:	22198621
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Nick Halverson
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	29-APR-2015
Filing Date:	30-JUN-2010
Time Stamp:	10:07:03
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$480
RAM confirmation Number	9774
Deposit Account	061050
Authorized User	FISH & RICHARDSON P C

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2001Resp.pdf	149720 ac7771e63418b50d54bf7e6859b0bfa523484e13	yes	3

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Transmittal Letter	1	2
Issue Fee Payment (PTO-85B)	3	3

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	30111 de070d2d4c49d6f70311d14d1979ecc9218d10c6	no	2

Warnings:

Information:

Total Files Size (in bytes):	179831

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	: 2491
Serial No.	:	12/827,745	Examiner	: Evans Desrosiers
Filed	:	June 30, 2010	Confirmation No.	: 5602
			Notice of Allowance Date: April 24, 2015	
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOTICE OF ALLOWANCE

In response to the Notice of Allowance dated April 24, 2015, attached is a completed Part B - Fee(s) Transmittal.

The issue fee in the amount of $480 is being paid with this reply on the Electronic Filing System. Apply those fees and any other necessary charges or credits to Deposit Account 06 1050, referencing the above attorney docket number.

COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE

It is recognized that in accordance with M.P.E.P. § 1302.14, the Examiner's reasons for allowance need not set forth all of the details as to why the claims are allowed. In the above-referenced application, it is not conceded that the Examiner's stated reasons for allowance are the only reasons for which the claims are allowable. The Examiner's reasons for allowance indicate that particular claim elements are not disclosed or suggested by the prior art of record, yet the claims may be patentable for other reasons as well, including the inventive combination of all of the recited claim elements. It is not conceded that the specific limitations identified by the Examiner are necessary to distinguish the art of record or to satisfy the requirements of 35 U.S.C. § 112. Moreover, the Examiner does not assert, and it would not be conceded, that the Examiner's reasons have any bearing on the patentability of claims in any other applications directed to the disclosed subject matter.

In addition, each dependent claim stands on its own and may be allowable on its own merits. In particular, each dependent claim may be allowable on the basis of a combination of some of the features recited in the dependent claim and its base claim(s), which combination of features may not include all of the limitations identified in the Examiner's reasons for allowance.

Respectfully submitted,

Date: 29 April 2015

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23386096.doc

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26161 7590 04/24/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER
DESROSIERS, EVANS

ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 04/24/2015

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

TITLE OF INVENTION: De-identifying Medical History Information for Medical Underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$480	$0	$0	$480	07/24/2015

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 04/24/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

TITLE OF INVENTION: De-identifying Medical History Information for Medical Underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$480	$0	$0	$480	07/24/2015

EXAMINER	ART UNIT	CLASS-SUBCLASS
DESROSIERS, EVANS	2491	713-168000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
- ❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.
1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:
- ❑ Issue Fee
- ❑ Publication Fee (No small entity discount permitted)
- ❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
- ❑ A check is enclosed.
- ❑ Payment by credit card. Form PTO-2038 is attached.
- ❑ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
- ❑ Applicant certifying micro entity status. See 37 CFR 1.29
  NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
- ❑ Applicant asserting small entity status. See 37 CFR 1.27
  NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
- ❑ Applicant changing to regular undiscounted fee status.
  NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 04/24/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 04/24/2015

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *03/11/2015*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *28-46*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____.
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date *01/28/2015*.
5. ☐ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. This communication is in respond to applicants' Request for Continued Examination filed on 03/11/2015.

Status of claims

2. Claims 1-46 are pending; of which claims 28-46 are allowed.

REASON FOR ALLOWANCE

3. The following is an examiner's statement of reasons for allowance:

None of the prior arts of record individually or in combination explicitly teach or fairly suggest the each and every claimed limitation of the current invention as amended by the applicant, especially the independent claim include "receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information; producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual; when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information

and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information"; in combination with all the elements of each independent claim as filed by Applicant on 03/11/2015. The claim has been considered persuasive, in light of its limitations, as well as enabling portions of the specification.

The dependent claims further limit the independent claims and are considered allowable on the same basis as the independent claims as well as for the further limitations set forth.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

4. **The prior art made of** record and not relied upon is considered pertinent to applicant's disclosure. These include.

- US 2006/0184524 A1 – Pollanz
- US 2005/0261941 A1 – Scarlat
- US 2009/0024416 A1- McLaughlin
- US 2011/0258000 A1 – GREEN et al.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	B	US-2006/0229919	10-2006	Pugh, Timothy	705/003
*	C	US-2006/0184524	08-2006	Pollanz, Gunter	707/006
*	D	US-2011/0258000	10-2011	GREEN et al.	705/3
*	E	US-2005/0261941	11-2005	Scarlat, Alexander	705/003
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

CPC						
Symbol					**Type**	**Version**
H04L		63	/	08	F	2013-01-01
H04L		63	/	0428	I	2013-01-01
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			
			/			

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
			/					
			/					

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491	04/19/2015	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	28	3

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

US ORIGINAL CLASSIFICATION		INTERNATIONAL CLASSIFICATION										
CLASS	SUBCLASS	CLAIMED					NON-CLAIMED				
713	168	H	0	4	L	9 / 32 (2006.01.01)	H	0	4	L	9 / 32 (2006.01.01)
CROSS REFERENCE(S)							H	0	4	L	29 / 06 (2006.01.01)
							G	0	6	F	1 / 26 (2006.01.01)
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)						G	0	8	B	13 / 00 (2006.01.01)
713	150	168									
726	36										
380	227										

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491	04/19/2015	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	28	3

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
-	1	-	17	6	33										
-	2	--	18	7	34										
-	3	-	19	8	35										
-	4	-	20	9	36										
-	5	-	21	10	37										
-	6	-	22	11	38										
-	7	-	23	12	39										
-	8	-	24	13	40										
-	9	-	25	14	41										
-	10	-	26	15	42										
-	11	-	27	16	43										
-	12	1	28	17	44										
--	13	2	29	18	45										
-	14	3	30	19	46										
-	15	4	31												
-	16	5	32												

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491 (Primary Examiner)	04/19/2015 (Date)	O.G. Print Claim(s) 28	O.G. Print Figure 3

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner
H04L63/08 H04L63/08 H04L9/08	4/19/2015	ED

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED
380	28-30,255-283	12/12/2013	ED
713	150-154,160-167,189-193	12/12/2013	ED
705	3, 5	12/12/2013	ED
380	28-30,255-283	5/5/2014	ED
713	150-154,160-167,189-193	5/5/2014	ED
705	3, 5	5/5/2014	ED
380	28-30,255-283	8/25/2014	ED
713	150-154,160-167,189-193	8/25/2014	ED
705	3, 5	8/25/2014	ED
713	150-154,160-167,189-193	2/5/2015	ED
705	3, 5	2/5/2015	ED
713	150-154,160-167,189-193	4/19/2015	ED
705	3-5	4/19/2015	ED

SEARCH NOTES		
Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED

SEARCH NOTES		
Search Notes	**Date**	**Examiner**
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	12/12/2013	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	5/5/2014	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	8/25/2014	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	2/5/2015	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	4/19/2015	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	**US Subclass / CPC Group**	**Date**	**Examiner**
713	150,168	2/5/2015	ED
726	36	2/5/2015	ED
713	150, 168	4/19/2015	ED
726	36	4/19/2015	ED

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary)		25412-0002001	12/827,745
		Applicant: Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date: June 30, 2010	Group Art Unit: 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2009/0070146	03/12/2009	Haider, et al.			
	2	2011/0225007	09/15/2011	Theis			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	3							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	4	

Examiner Signature	Date Considered
/Evans Desrosiers/	04/18/2015

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014	08/25/2014	02/05/2015	04/19/2015		
-	1	✓	✓	✓	✓	✓	-	-		
-	2	✓	✓	✓	✓	✓	-	-		
-	3	✓	✓	✓	✓	✓	-	-		
-	4	✓	✓	✓	✓	✓	-	-		
-	5	✓	✓	✓	✓	✓	-	-		
-	6	✓	✓	✓	✓	✓	-	-		
-	7	✓	✓	✓	✓	✓	-	-		
-	8	✓	✓	✓	✓	✓	-	-		
-	9	✓	✓	✓	✓	✓	-	-		
-	10	✓	✓	✓	✓	✓	-	-		
-	11	✓	✓	✓	✓	✓	-	-		
-	12	✓	✓	✓	✓	✓	-	-		
-	13	✓	✓	✓	✓	✓	-	-		
-	14	✓	✓	✓	✓	✓	-	-		
-	15	✓	✓	✓	✓	✓	-	-		
-	16	✓	✓	✓	✓	✓	-	-		
-	17	✓	✓	✓	✓	✓	-	-		
-	18	✓	✓	✓	✓	✓	-	-		
-	19	✓	✓	✓	✓	✓	-	-		
-	20	✓	✓	✓	✓	✓	-	-		
-	21	✓	✓	✓	✓	✓	-	-		
-	22	✓	✓	✓	✓	✓	-	-		
-	23	✓	✓	✓	✓	✓	-	-		
-	24	✓	✓	✓	✓	✓	-	-		
-	25	✓	✓	✓	✓	✓	-	-		
-	26	✓	✓	✓	✓	✓	-	-		
-	27	✓	✓	✓	✓	✓	-	-		
1	28			✓	✓	✓	=	=		
2	29			✓	✓	✓	=	=		
3	30				✓	✓	=	=		
4	31						=	=		
5	32						=	=		
6	33						=	=		
7	34						=	=		
8	35						=	=		
9	36						=	=		

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014	08/25/2014	02/05/2015	04/19/2015		
10	37						=	=		
11	38						=	=		
12	39						=	=		
13	40						=	=		
14	41						=	=		
15	42						=	=		
16	43						=	=		
17	44						=	=		
18	45						=	=		
19	46						=	=		

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT;	OR	OFF	2012/05/30 15:30

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT;	OR	OFF	2012/05/30 17:58

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:04

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:17

		same (medical near5 record)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:43

		group)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT;	OR	OFF	2013/12/06 10:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT;	OR	OFF	2013/12/06 11:23

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5	US-PGPUB; USPAT;	OR	OFF	2013/12/12 11:58

		authoriz$5	USOCR; FPRS; EPO; JPO; IBM_TDB			
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT;	OR	OFF	2013/12/12 12:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 14:30
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:06
S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:07

			JPO; IBM_TDB			
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:39
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:43

			JPO; IBM_TDB			
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 16:07
S118	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:27
S119	3	US-20060004772-$.DID. OR US-20080147554-$.DID. OR US-20110184748-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 08:49
S120	2	US-20090070146-$.DID. OR US-20110225007-$.DID.	US-PGPUB; USPAT	OR	OFF	2015/04/18 09:27
S121	6	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S122	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S123	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S124	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S125	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S126	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S127	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S128	2	S122 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S129	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S130	14	S125 and S129	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S131	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S132	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S133	64	S131 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S134	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S135	72	S134 and (@pd or @ptad or @prad or @ad or	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

		@rlad)<"20090701"	USOCR; FPRS; EPO; JPO; IBM_TDB			
S136	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S137	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S138	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S139	2	S138 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S140	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S141	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S144	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S145	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S146	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S148	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S149	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S151	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S152	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S154	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S155	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S157	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S158	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S159	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S160	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S161	38	S159 and ((number quantity) near5 (patient individual) near5	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

		group)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S163	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S164	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S165	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S166	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S168	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S170	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S172	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S173	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S175	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S176	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S178	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S179	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S181	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S184	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S185	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S186	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S188	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S191	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S192	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S194	47	(produce producing produced output) near5 (information data	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

		record) same (patient individual) near5 un$1authoriz$5	USOCR; FPRS; EPO; JPO; IBM_TDB			
S195	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S197	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S198	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S199	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S201	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S202	17144346	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S204	181	S201 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S206	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S207	0	S206 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S208	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S209	10	S206 and S208	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S217	5888	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S218	229	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S219	229	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S220	301	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S221	56	S217 and S220	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S223	3151	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S224	21400	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S226	1722	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S227	8495	S224 and (access$5 near5 (patient individual group) near5 medical	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:42

		near5 (information data record) same without (permision authoriz$5))	USOCR; FPRS; EPO; JPO; IBM_TDB			
S228	8	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S230	156	S224 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:42
S238	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S239	347	S122 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S240	27	S123 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S241	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S242	0	S123 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S243	0	S124 and S125	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S245	1861	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S247	13377	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S248	455	S131 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S250	97	S131 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S253	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S254	70	S137 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S256	99	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S257	70	S140 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S260	8730	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S261	268	S144 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S262	4439	S145 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S264	308	S144 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S265	502	S144 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S267	512	S144 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S268	199	S151 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S270	8127	S144 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S271	39	S144 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S273	260216	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S274	626	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S275	377	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S276	0	S159 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S277	38	S159 and ((number quantity) near5 (patient individual) near5	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

		group)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S279	162742	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S280	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S281	47956	S163 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S282	47956	S163 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S284	147536	S163 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S286	209	S163 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S288	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S289	0	S162 and S172	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S291	326	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S292	52	S175 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S294	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S295	42268	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S297	55246	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S300	170	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S301	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S302	78	S184 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S304	0	S187 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S307	725	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S308	586	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S310	47	(produce producing produced output) near5 (information data	US-PGPUB; USPAT;	OR	OFF	2015/04/19 14:44

		record) same (patient individual) near5 un$1authoriz$5	USOCR; FPRS; EPO; JPO; IBM_TDB			
S311	0	S191 and S194	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S313	0	S191 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S314	1322	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S315	0	S198 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44
S317	229	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2015/04/19 14:44

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13812	(H04L63/08 H04L63/08 H04L9/08).CPC.	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:54
L2	0	1 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:56
S114	10371	713/150,168.ccls. 380/ccls. 726/36.ccls.	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:31
S115	0	S114 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:31
S116	9	S114 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:32
S117	9	S116 and (@pd or @ptad or @prad or	US-	OR	OFF	2015/02/05

		@ad or @rlad)<"20090701"	PGPUB; USPAT; UPAD			12:32
S318	10646	713/150,168.ccls. 380/ccls. 726/36.ccls.	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:42
S319	0	S318 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:42
S320	9	S318 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:42
S321	9	S320 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; UPAD	OR	OFF	2015/04/19 14:42

4/ 19/ 2015 2:57:12 PM
C:\ Users\ edesrosiers\ Documents\ EAST\ Workspaces\ 12827745.wsp

PTO/SB/30 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	12/827,745
Filing Date	June 30, 2010
First Named Inventor	Andrew L. Paris III
Art Unit	2491
Examiner Name	Evans Desrosiers
Attorney Docket Number	25412-0002001

This is a Request for Continued Examination (RCE) under 37 CFR 1 .114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

   a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

      i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

      ii. ☐ Other _____

   b. ☒ Enclosed

      i. ☐ Amendment/Reply

      ii. ☐ Affidavit(s)/ Declaration(s)

      iii. ☒ Information Disclosure Statement (IDS)

      iv. ☐ Other _____

2. Miscellaneous

   Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

   a. ☐ period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

   b. ☐ Other _____

3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
   The Director is hereby authorized to charge the following fees any underpayment of fees or credit any overpayments to

   a. ☒ Deposit Account No. 06-1050 .

      i. ☒ RCE fee required under 37 CFR 1.17(e)

      ii ☐ Extension of time fee (37 CFR 1.136 and 1.17)

      iii ☒ Other any deficiencies

   b. ☐ Check in the amount of $ _____ enclosed

   c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/	Date	11 March 2015
Name (Print/Type)	Jeffrey J. Barclay	Registration No.	48,950

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature			
Name (Print/Type)		Date	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkFlow.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This filing is being made with the filing of a Request for Continued Examination. No fee is required.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 11 March 2015

/Jeffrey J. Barclay, Reg, No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23364854.doc

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2009/0070146	03/12/2009	Haider, et al.			
	2	2011/0225007	09/15/2011	Theis			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	3							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	4	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
RCE- 2nd and Subsequent Request	2820	1	850	850
		Total in USD ($)		**850**

Electronic Acknowledgement Receipt

EFS ID:	21735744
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	11-MAR-2015
Filing Date:	30-JUN-2010
Time Stamp:	12:20:08
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$850
RAM confirmation Number	9664
Deposit Account	061050
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	2001RCE.pdf	108429 518d03938213cc0ae0e03a47cd5831ff7202f6d4	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		2001IDS.pdf	115712 4245e23e88dec9191e91eba0c9c10ff0db5f2a7f	yes	2

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Information Disclosure Statement (IDS) Form (SB08)	2	2

Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	30323 96b01f16a586688899d724a0354f0e40bfc0c39b	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	254464		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 12/827,745	Filing Date 06/30/2010	☐ To be Mailed

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **03/11/2015**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 19	Minus	** 30	= 0	X $40 =	0
Independent (37 CFR 1.16(h))	* 3	Minus	***4	= 0	X $210 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/DONNA 1. SMALLS LOGAN/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26161 7590 02/13/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER
DESROSIERS, EVANS

ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 02/13/2015

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

TITLE OF INVENTION: De-identifying Medical History Information for Medical Underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$480	$0	$0	$480	05/13/2015

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

26161 7590 02/13/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

TITLE OF INVENTION: De-identifying Medical History Information for Medical Underwriting

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	SMALL	$480	$0	$0	$480	05/13/2015

EXAMINER	ART UNIT	CLASS-SUBCLASS
DESROSIERS, EVANS	2491	713-168000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).
- ❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.
1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. The following fee(s) are submitted:
- ❑ Issue Fee
- ❑ Publication Fee (No small entity discount permitted)
- ❑ Advance Order - # of Copies _____

4b. Payment of Fee(s): **(Please first reapply any previously paid issue fee shown above)**
- ❑ A check is enclosed.
- ❑ Payment by credit card. Form PTO-2038 is attached.
- ❑ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. **Change in Entity Status** (from status indicated above)
- ❑ Applicant certifying micro entity status. See 37 CFR 1.29 — NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
- ❑ Applicant asserting small entity status. See 37 CFR 1.27 — NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
- ❑ Applicant changing to regular undiscounted fee status. — NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Datavant Exhibit 1002

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 02/13/2015
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

DATE MAILED: 02/13/2015

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*. (3)_____.

(2) *Jeffrey Barclay* . (4)_____.

Date of Interview: *28 January 2015*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☒112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *28*.

Identification of prior art discussed: *Pugh US 20060229919 A1, McLaughlin: US 20090024416 20060229919 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

In an effort to expedite prosecution, the Examiner reached out to Applicant representative .Scondly , the Examiner suggested to Applicant representative Mr. Jeffrey Barclay potential amendment to independent claim 28. In response, the Applicant representative agreed to amend the claim via Examiner's amendment in order to place the application in condition for allowance.

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Notice of Allowability	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to *10/27/2014*.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on_____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are *28-46*. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov .
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:
   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
4. ☒ Interview Summary (PTO-413), Paper No./Mail Date *01/28/2015* .
5. ☒ Examiner's Amendment/Comment
6. ☒ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. This communication is in respond to applicants' arguments filed on 10/27/2014.

Status of claims

2. Claims 1-46 are pending; of which claims 28-46 are allowed.

EXAMINER'S AMENDMENT

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given via email on 02/03/2015 by applicants' representative Jeffrey Barclay (Reg. No. 48,950).

4. The application has been amended as follows:

Please cancel claims 1-27.

Please add Claims 31-46

Please amend claim 1 as follows:

5. Proposed amended claim set for Application No. 12/827,745 (Second set – sent 3 February 2015)

1. – 27. (Cancelled)

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, ~~unique identifiers~~ tokens, wherein the identity of the individuals in the group is unattainable from the ~~unique identifiers~~ tokens, each token being associated with an individual in the group, each ~~unique identifier~~ token being associated with a corresponding ~~unique identifier~~ token in a set of de-identified healthcare data, and each ~~unique identifier~~ token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the ~~unique identifiers~~ tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced ~~unique identifiers~~ tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of

individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

31. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

32. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

33. (New) The computer-implemented method of claim 28, in which the healthcare data represents medical related information associated with the individuals of the group.

34. (New) A system comprising:

an encryption server, having a processor and a memory, for producing a token for each individual included in a group composed of multiple individuals identified in a request for healthcare information that characterizes the group, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

a data server for producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

35. (New) The system of claim 34, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

36. (New) The system of claim 34, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

37. (New) The system of claim 34, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

38. (New) The system of claim 34, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

39. (New) The system of claim 34, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

40. (New) The system of claim 34, in which the healthcare data represents medical related information associated with the individuals of the group.

41. (New) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

42. (New) The computer readable storage devices of claim 41, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

43. (New) The computer readable storage devices of claim 41, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

44. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

45. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

46. (New) The computer readable storage devices of claim 41, in which the healthcare data represents medical related information associated with the individuals of the group.

REASON FOR ALLOWANCE

6. The following is an examiner's statement of reasons for allowance:

None of the prior arts of record individually or in combination explicitly teach or fairly suggest the each and every claimed limitation of the current invention as amended by the applicant, especially the independent claim include "receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information; producing, by a processor of an encryption server, -tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual; when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted,

and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information"; in combination with all the elements of each independent claim as amended by Applicant on 02/03/2015. The claim has been considered persuasive, in light of its limitations, as well as enabling portions of the specification.

The dependent claims further limit the independent claims and are considered allowable on the same basis as the independent claims as well as for the further limitations set forth.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is

571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*. (3)_____.

(2) *Jeffrey Barclay* . (4)_____.

Date of Interview: *28 January 2015*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☒112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *28*.

Identification of prior art discussed: *Pugh US 20060229919 A1, McLaughlin: US 20090024416 20060229919 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

In an effort to expedite prosecution, the Examiner reached out to Applicant representative .Scondly , the Examiner suggested to Applicant representative Mr. Jeffrey Barclay potential amendment to independent claim 28. In response, the Applicant representative agreed to amend the claim via Examiner's amendment in order to place the application in condition for allowance.

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	B	US-2006/0229919	10-2006	Pugh, Timothy	705/003
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Desrosiers, Evans

From: Jeffrey Barclay <Barclay@fr.com>
Sent: Tuesday, February 03, 2015 2:42 PM
To: Desrosiers, Evans
Cc: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)
Attachments: Proposed claim set for US Application 12_827_745 (second set for 3 February 2015).doc

Examiner Desrosiers,

Thank you again for the telephone call today.

As we discussed, the claim amendments have been adjusted as we discussed.
Please find attached one MS-Word document that contains the adjusted claim set. This is the second set of claims that has been sent to you today, 3 February 2015.
Please feel free to call me at any time. I'll also call you right now.

Thanks again for your time in this matter,

Jeff

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

From: Jeffrey Barclay
Sent: Tuesday, February 03, 2015 11:44 AM
To: 'Desrosiers, Evans'
Cc: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thank you again for our telephone call yesterday.

The applicant and I were able to have a telephone conversation this morning and discuss the claims.
Please find attached one MS-Word document that contains a proposed claim set based on your message (below).
Please feel free to call me at any time. I'll also call you right now.

Thanks again for your time in this matter,

Jeff

Datavant Exhibit 1002
Page 131 of 468

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

From: Desrosiers, Evans [mailto:evans.desrosiers@USPTO.GOV]
Sent: Saturday, January 31, 2015 1:52 PM
To: Jeffrey Barclay
Subject: RE: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Hi Jeffrey,

Please find attached the amendment which is from the specification paragraph [0022], if you agree please let me know. Also, there is an obviousness double patenting for No. 14/080,433.

Thank you,

Evans Desrosiers
Primary Patent Examiner
U.S. Patent & Trademark Office
500 Dulany St. Office 9D31
(571) 270-5438
Fax (571) 270-6438
Evans.Desrosiers@uspto.gov

From: Jeffrey Barclay [mailto:Barclay@fr.com]
Sent: Friday, January 30, 2015 12:18 PM
To: Desrosiers, Evans
Cc: Jeffrey Barclay
Subject: Proposed claim set for US Patent Application Serial No. 12/827,745 (F&R 25412-0002001)

Examiner Desrosiers,

Thank you again for our telephone conversations this week.

Please find attached one MS-Word document that contains a proposed claim set including the amendments we discussed yesterday. Please feel free to call me at any time.
I'll also call you right now.

Thanks again for your time in this matter,

Jeff

Jeffrey Barclay :: Principal
Fish & Richardson P.C.
+1-617-368-2191 direct :: Barclay@fr.com
fr.com

****
****
This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.
****
****

****
****
This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.
****
****

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	2							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	3	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages.
	4	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html, (accessed 10/09/2014), 2 pages.

Examiner Signature	Date Considered
/Evans Desrosiers/	02/05/2015

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2006/0004772	01/2006	Hagan, et al.			
	2	2008/0147554	06/2008	Stevens, et al.			
	3	2011/0184748	07/2011	Fierro, et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	4							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	5	

Examiner Signature	Date Considered
/Evans Desrosiers/	02/05/2015

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Proposed amended claim set for Application No. 12/827,745
(Second set – sent 3 February 2015)

1. – 27. (Cancelled)

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, ~~unique identifiers~~ tokens, wherein the identity of the individuals in the group is unattainable from the ~~unique identifiers~~ tokens, each token being associated with an individual in the group, each ~~unique identifier~~ token being associated with a corresponding ~~unique identifier~~ token in a set of de-identified healthcare data, and each ~~unique identifier~~ token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the ~~unique identifiers~~ tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced ~~unique identifiers~~ tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

31. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

32. (New) The computer-implemented method of claim 28, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

33. (New) The computer-implemented method of claim 28, in which the healthcare data represents medical related information associated with the individuals of the group.

34. (New) A system comprising:

an encryption server, having a processor and a memory, for producing a token for each individual included in a group composed of multiple individuals identified in a request for healthcare information that characterizes the group, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with a corresponding token in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

a data server for producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

35. (New) The system of claim 34, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

36. (New) The system of claim 34, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

37. (New) The system of claim 34, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

38. (New) The system of claim 34, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

39. (New) The system of claim 34, in which producing the requested healthcare information includes determining if the group includes at least a minimum number of individuals.

40. (New) The system of claim 34, in which the healthcare data represents medical related information associated with the individuals of the group.

41. (New) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information;

producing, by a processor of an encryption server, tokens, wherein the identity of the individuals in the group is unattainable from the tokens, each token being associated with an individual in the group, each token being associated with a corresponding token

in a set of de-identified healthcare data, and each token in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

when the group includes at least a minimum number of individuals, producing the requested healthcare information that characterizes the group by identifying the tokens in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced tokens, wherein the produced tokens and the tokens in the set of de-identified data are similarly encrypted, and the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the requested healthcare information.

42. (New) The computer readable storage devices of claim 41, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

43. (New) The computer readable storage devices of claim 41, wherein the request for healthcare information that characterizes a group of individuals from healthcare data includes personally identifiable information associated with members of the group of individuals.

44. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes encrypting respective data that identifies each individual.

45. (New) The computer readable storage devices of claim 41, in which producing the requested healthcare information includes identifying at least a minimum number of corresponding tokens.

46. (New) The computer readable storage devices of claim 41, in which the healthcare data represents medical related information associated with the individuals of the group.

23349488.doc

Datavant Exhibit 1002
Page 140 of 468

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT;	OR	OFF	2012/05/30 15:30

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT;	OR	OFF	2012/05/30 17:58

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:04

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:17

		same (medical near5 record)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:43

		group)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT;	OR	OFF	2013/12/06 10:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT;	OR	OFF	2013/12/06 11:23

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5	US-PGPUB; USPAT;	OR	OFF	2013/12/12 11:58

		authoriz$5	USOCR; FPRS; EPO; JPO; IBM_TDB			
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT;	OR	OFF	2013/12/12 12:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 14:30
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:06
S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:07

			JPO; IBM_TDB			
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:39
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:43

			JPO; IBM_TDB			
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 16:07

EAST Search History (Interference)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	10371	713/150,168.ccls. 380/ccls. 726/36.ccls.	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:31
L2	0	1 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:31
L3	9	1 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:32
L4	9	3 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; UPAD	OR	OFF	2015/02/05 12:32

2/5/2015 12:33:04 PM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014	08/25/2014	02/05/2015			
-	1	✓	✓	✓	✓	✓	-			
-	2	✓	✓	✓	✓	✓	-			
-	3	✓	✓	✓	✓	✓	-			
-	4	✓	✓	✓	✓	✓	-			
-	5	✓	✓	✓	✓	✓	-			
-	6	✓	✓	✓	✓	✓	-			
-	7	✓	✓	✓	✓	✓	-			
-	8	✓	✓	✓	✓	✓	-			
-	9	✓	✓	✓	✓	✓	-			
-	10	✓	✓	✓	✓	✓	-			
-	11	✓	✓	✓	✓	✓	-			
-	12	✓	✓	✓	✓	✓	-			
-	13	✓	✓	✓	✓	✓	-			
-	14	✓	✓	✓	✓	✓	-			
-	15	✓	✓	✓	✓	✓	-			
-	16	✓	✓	✓	✓	✓	-			
-	17	✓	✓	✓	✓	✓	-			
-	18	✓	✓	✓	✓	✓	-			
-	19	✓	✓	✓	✓	✓	-			
-	20	✓	✓	✓	✓	✓	-			
-	21	✓	✓	✓	✓	✓	-			
-	22	✓	✓	✓	✓	✓	-			
-	23	✓	✓	✓	✓	✓	-			
-	24	✓	✓	✓	✓	✓	-			
-	25	✓	✓	✓	✓	✓	-			
-	26	✓	✓	✓	✓	✓	-			
-	27	✓	✓	✓	✓	✓	-			
1	28			✓	✓	✓	=			
2	29			✓	✓	✓	=			
3	30				✓	✓	=			
4	31						=			
5	32						=			
6	33						=			
7	34						=			
8	35						=			
9	36						=			

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014	08/25/2014	02/05/2015			
10	37						=			
11	38						=			
12	39						=			
13	40						=			
14	41						=			
15	42						=			
16	43						=			
17	44						=			
15	45						=			
19	46						=			

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

CPC		
Symbol	**Type**	**Version**

CPC Combination Sets				
Symbol	**Type**	**Set**	**Ranking**	**Version**

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491	02/05/2015	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	28	3

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

US ORIGINAL CLASSIFICATION		INTERNATIONAL CLASSIFICATION										
CLASS	SUBCLASS	CLAIMED					NON-CLAIMED				
713	168	H	0	4	L	9 / 32 (2006.01.01)	H	0	4	L	9 / 32 (2006.01.01)
							H	0	4	L	29 / 06 (2006.01.01)
							G	0	6	F	1 / 26 (2006.01.01)
							G	0	8	B	13 / 00 (2006.01.01)

CROSS REFERENCE(S)					
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
713	150	168			
726	36				
380	227				

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491	02/05/2015	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	28	3

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
-	1	-	17	6	33										
-	2	--	18	7	34										
-	3	-	19	8	35										
-	4	-	20	9	36										
-	5	-	21	10	37										
-	6	-	22	11	38										
-	7	-	23	12	39										
-	8	-	24	13	40										
-	9	-	25	14	41										
-	10	-	26	15	42										
-	11	-	27	16	43										
-	12	1	28	17	44										
--	13	2	29	18	45										
-	14	3	30	19	46										
-	15	4	31												
-	16	5	32												

NONE (Assistant Examiner)	(Date)	**Total Claims Allowed:** 19	
/EVANS DESROSIERS/ Primary Examiner.Art Unit 2491 (Primary Examiner)	02/05/2015 (Date)	O.G. Print Claim(s) 28	O.G. Print Figure 3

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED
380	28-30,255-283	12/12/2013	ED
713	150-154,160-167,189-193	12/12/2013	ED
705	3, 5	12/12/2013	ED
380	28-30,255-283	5/5/2014	ED
713	150-154,160-167,189-193	5/5/2014	ED
705	3, 5	5/5/2014	ED
380	28-30,255-283	8/25/2014	ED
713	150-154,160-167,189-193	8/25/2014	ED
705	3, 5	8/25/2014	ED
713	150-154,160-167,189-193	2/5/2015	ED
705	3, 5	2/5/2015	ED

SEARCH NOTES		
Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED

SEARCH NOTES		
Search Notes	**Date**	**Examiner**
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	12/12/2013	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	5/5/2014	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	8/25/2014	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	2/5/2015	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	**US Subclass / CPC Group**	**Date**	**Examiner**
713	150,168	2/5/2015	ED
726	36	2/5/2015	ED

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2006/0004772	01/2006	Hagan, et al.			
	2	2008/0147554	06/2008	Stevens, et al.			
	3	2011/0184748	07/2011	Fierro, et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	4							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	5	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Submission- Information Disclosure Stmt	2806	1	90	90
		Total in USD ($)		**90**

Electronic Acknowledgement Receipt

EFS ID:	21030839
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	22-DEC-2014
Filing Date:	30-JUN-2010
Time Stamp:	11:52:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$90
RAM confirmation Number	12142
Deposit Account	061050
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2001.pdf	120515 8dd9cbd51816f68d608c17c0e36b9d687fab2736	yes	2

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Transmittal Letter	1	1
Information Disclosure Statement (IDS) Form (SB08)	2	2

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	30271 11f07d20d62fceb044ba7dd82f33c2fb54126ff8	no	2

Warnings:

Information:

Total Files Size (in bytes):	150786

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This statement is being filed after a first action on the merits, but before receipt of a final action or a notice of allowance. A late submission fee in the amount of $90, specified by 37 CFR §1.17(p), is being paid with this statement.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 22 December 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23336743.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF AUGUST 29, 2014

Please consider the following reply.

List of claims (replacing prior versions).

1. (Previously Presented) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Previously Presented) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Previously Presented) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises ~~personally identifiable~~ de-identified information;

producing, by a processor, ~~individual~~ unique identifiers, wherein the identity of the individuals in the group is unattainable from the ~~individual~~ unique identifiers, each ~~individual~~ unique identifier being associated with a corresponding ~~individual~~ unique identifier in a set of de-identified healthcare data, and each ~~individual~~ unique identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing~~, absent authorization from the group of individuals at any time,~~ the requested healthcare information that characterizes the group by identifying the ~~individual~~ unique identifiers in the set of de-identified healthcare data and the associated de-identified

healthcare data that correspond to the produced ~~individual~~ unique identifiers, wherein the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group; and

providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the ~~group of~~ individuals in the group of individuals ~~at any time~~ to provide the requested healthcare information.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

REMARKS

The undersigned representative thanks Examiner Desrosiers for the courtesy of the telephonic interview held on September 22, 2014 with the undersigned representative and Natalie Galley. Along with discussing the current action, the pending claims and art references cited in the action were also discussed.

During the interview, the Examiner stated that claim 1 was too broad, and was therefore not patentable. However, with respect to broad claims, the MPEP states that

> "[u]ndue breadth of the claim may be addressed under different statutory provisions, depending on the reasons for concluding that the claim is too broad…If the claim is too broad because it reads on the prior art, a rejection under either 35 U.S.C. 102 or 103 would be appropriate." See MPEP § 2173.04.

The MPEP does not state that a claim is unpatentable simply because it is broad, but that a broad claim should be rejected if it reads on the prior art. However, during the interview the Applicant's representative explained that elements of independent claim 1 are not believed to be shown in the cited references.

The Interview Summary dated September 26, 2014 states that "Examiner explained to the Applicant how the claimed limitation has been interpreted." Applicant's representative respectfully disagrees. The Examiner was not understood to provide his interpretation beyond stating that independent claim 1 is broad.

The Interview Summary further states that "Applicant agreed to amend the claim, and will submit an official amendment." Applicant's representative respectfully disagrees. Applicant's representative stated during the interview that given the contradictory language of the current Office Action, a claim amendment could not be proposed. However, to forward prosecution, Applicant has included amendments to the claims as shown and discussed below.

Claims 1-30 are pending in this application, with claims 1, 10, 19, and 28 being independent. Favorable reconsideration and further examination is respectfully requested in view of the following amendments and comments of the Applicant, which are preceded by related comments of the Examiner in small bold type.

Claim 1-6, 9-15, 18-24, 27 rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Pugh US 20060229919 Al in view of McLaughlin: US 20090024416 Al.

Independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

Pugh is understood to describe a system for creating, maintaining and selectively accessing medical histories (please see abstract). In Pugh's system, the patient has sole control over his or her medical information and the patient must grant permission to a third person such as a medical provider before any information can be accessed and viewed.

Page 3 of the Office Action states that "information that characterizes a group of individuals" has been interpreted as a "patient's medical history." Thus, the claimed producing "information that characterizes a group of individuals" has been equated to producing a single patient's medical history. However, the MPEP states that:

> "[u]der a broadest reasonable interpretation, words of the claim must be given their plain meaning, unless such meaning is inconsistent with the specification. The plain meaning of a term means the ordinary and customary meaning given to the term by those of ordinary skill in the art at the time of the invention. The ordinary and customary meaning of a term may be evidenced by a variety of sources, including the words of the claims themselves, the specification, drawings, and prior art." See MPEP 2111.01.

One of ordinary skill in the art would not interpret "information that characterizes a group of individuals" to be a single person's medical history, as the plain meaning of the word "group" means more than one individual (see, e.g., American Heritage Dictionary, definition of group: 1. An assemblage of persons or objects gathered or located together; 2. A set of two or more figures that make up a unit or design, as in sculpture. 3. A number of individuals or things considered or classed together because of similarities). Further, the specification itself makes clear that the claimed "group" is more than one person. For example, the specification states that "[i]f such a minimum number of matches has not occurred in comparing the request tokens…action may be

taken…until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified)" (please see paragraph [034]). The skilled person would therefore understand that in the context of the claim, the characteristics of the group cannot be equated to a single person's history.

Page 3 of the Office Action points out that Pugh states that his system "can be accessed in the event of an emergency without *further* consent of the patient *as they have authorized such access when they first created their patient file.*" (See Pugh, paragraph [0045]). As both Pugh and the Office Action state, Pugh's system explicitly requires that the patient gives access/authorization/permission when the patient's file is created. Applicant is unaware of any interpretation that the claimed "absent authorization from the group of individuals at any time" can be interpreted as "authorized when they created their patient file".

Applicant submits that Pugh does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1.

Additionally, McLaughlin is not understood to remedy these deficiencies of Pugh.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Pugh and McLaughlin. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pugh: US 20060229919 Al in view of McLaughlin: US 20090024416 Al in further view of Scarlat US 20050261941 Al.

Scarlat is not understood to remedy the foregoing deficiencies of Pugh and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]).

Similar to Pugh and McLaughlin, Scarlat does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Pugh, McLaughlin and Scarlat. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 7, 8, 16, 17, 25, and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pugh: US 20060229919 Al in view of McLaughlin: US 20090024416 Al in further view of GREEN, US 20110258000 Al.

Similarly, Pugh and McLaughlin are not understood to disclose or suggest the features of amended independent claim 28, namely, a computer-implemented method comprising receiving a request for healthcare information that characterizes a group composed of multiple individuals, the healthcare information being assembled from healthcare data that comprises de-identified information, producing, by a processor, unique identifiers, wherein the identity of the individuals in the group is unattainable from the unique identifiers, each unique identifier being associated with a corresponding unique identifier in a set of de-identified healthcare data, and each unique identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual, producing the requested healthcare information that characterizes the group by identifying the unique identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced unique identifiers, wherein the produced healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group, and providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent

authorization at any time from the individuals in the group of individuals to provide the produced healthcare information.

Green is not understood to remedy the foregoing deficiencies of Pugh and McLaughlin. Rather, Green teaches a system for recruiting participants for medical research including querying de-identified patient diagnosis/medical history data and determining the number of patients with specific diagnoses (see abstract and paragraph [0060]). Green also includes explicit authorization being given by the patient:

> "When an IPI user becomes a research client of the IPI provider, the IPI user not only authorizes research partners of the IPI provider to access patient-specific data for the IPI user's patient population, the IPI user is also given access to the infrastructure within the IPI 100 that interconnects all of the systems of the IPI 100 to the IPI provider's research partners' research systems" (paragraph [0070])
>
> "Verifying that a research client's qualifying patients 310 are eligible for the clinical trial may also include having the qualifying patients 310 sign a consent form, pre-populated with the required HIPAA-mandated language regarding the patients' protected information, authorizing their physician to place each patient's information on the Research Network" (paragraph [0076]).

Green, like Pugh and McLaughlin, fails to teach producing healthcare information is absent personally identifiable information and has been produced without the individuals in the group having authorized production of such healthcare information that characterizes the group, or providing the produced healthcare information to report the characteristics of the group composed of multiple individuals absent authorization at any time from the individuals in the group of individuals to provide the produced healthcare information.

Regarding dependent claim 29, the Examiner cites Pugh, paragraph [0038], which mentions the Health Insurance Portability and Accountability Act (HIPAA). However, paragraph [0038] in full states that:

> "The patient controls the level of access to his medical history, either allowing the access to his entire medical history maintained on IMED or to some subset of the information, at his own discretion. By allowing the patient to control the access to his own medical history either at the time the medical treatment is

> sought or by pre-authorization in the case of emergency, the present invention meets all HIPAA requirements ensuring the appropriate level of privacy and confidentiality related to the patient's medical information."

Pugh allows access to the patient's file after authorization (either at time of treatment or pre-authorized) in order to conform with HIPAA. Pugh does not disclose or suggest a computer-implemented method wherein the healthcare information provided absent authorization from the group of individuals is in conformity with HIPAA, as recited in claim 29.

The dependent claim 30 partakes of the novelty of independent claim 28 and, as such, has not been addressed specifically herein.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

No fees are believed due at this time. Please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 27 October 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23282600.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This statement is being filed after a first action on the merits, but before receipt of a final action or a notice of allowance. A late submission fee in the amount of $90, specified by 37 CFR §1.17(p), is being paid with this statement.

Apply any necessary charges or credits to deposit account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 27 October 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23308103.doc

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	2							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	3	"Group," The American Heritage Dictionary, 2014 Houghton Mifflin Harcourt, Retrieved online: https://ahdictionary.com/word/search.html?q=group (accessed 10/23/2014), 3 pages.
	4	"Health Information Privacy: Business Associates," U.S. Department of Health and Human Services, April 3, 2003, Retrieved online: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/businessassociates.html, (accessed 10/09/2014), 2 pages.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 1 month with $0 paid	2251	1	100	100

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Submission- Information Disclosure Stmt	2806	1	90	90
		Total in USD ($)		**190**

Electronic Acknowledgement Receipt

EFS ID:	20518844
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	27-OCT-2014
Filing Date:	30-JUN-2010
Time Stamp:	10:46:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$190
RAM confirmation Number	7989
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Exhibit 1002

1		2001Resp.pdf	133177 ebb77d35560ffe5e511e77659884b54a91d0772f	yes	13

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	13

Warnings:

Information:

2		2001IDS.pdf	127553 d34eed3affa98185fcce8cec0a9499211a72fb29	yes	2

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Information Disclosure Statement (IDS) Form (SB08)	2	2

Warnings:

Information:

3	Non Patent Literature	Group_AHD_102314.pdf	439009 4a0cbb4fc083f4883f5fb894ad9629f79378d7b5	no	3

Warnings:

Information:

4	Non Patent Literature	HealthInformationPrivacy.pdf	88594 952104cd7fcff78c50b9c0993937f47290770eda	no	2

Warnings:

Information:

5	Fee Worksheet (SB06)	fee-info.pdf	31977 44740478b53bc46f5d5c7433f37b2043e6f5d34a	no	2

Warnings:

Information:

Total Files Size (in bytes):	820310

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 12/827,745	Filing Date 06/30/2010	☒ To be Mailed

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **10/27/2014**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 30	Minus	** 30	= 0	X $40 =	0
Independent (37 CFR 1.16(h))	* 4	Minus	***4	= 0	X $210 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/LISA THOMAS/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 09/26/2014
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	**PAPER NUMBER**
2491	

NOTIFICATION DATE	DELIVERY MODE
09/26/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(3) *Jeff Barclay*.

(2) *Natalie Galley*.

(4)_____.

Date of Interview: *22 September 2014*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☐112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1*.

Identification of prior art discussed: *Pugh 20060229919 A1, McLaughlin: US 20090024416* .

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art and potential amendments to overcome the prior arts cited. Claim 1 was discussed. Applicant provided the analysis of the claim. Applicant argued that the Pugh's reference does not disclose "producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time" Examiner explained to the Applicant how the claimed limitation has been interpreted. Finaly, Applicant agreed to amend the claim, and will submit an official amendment. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Primary Examiner, Art Unit 2491	

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 08/29/2014
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
08/29/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *08/19/2014*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-30* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-30* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *6/30/2010* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. Claims 1-30 remain for examination. Claims 1-30 have been amended. Applicant's arguments filed on 08/19/2014 have been fully considered and they are persuasive. The finality rejection has been redrawn. Accordingly, this action has been made Non-final.

Examiner's Note

2. Examiner has cited particular columns and line numbers in the references as applied to the claims for the convenience of the applicant. Although the specified citations are representative of the teachings of the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested from the applicant in preparing responses, to fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the Examiner.

Response to Arguments

3. Applicant's arguments with respect to amended claims have been fully considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

4. Claim 1-6, 9-15, 18-24, 27 rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Pugh US 20060229919 A1 in view of McLaughlin: US 20090024416 A1.

5. **As to claim 1**, **Pugh** teaches a computer-implemented method comprising: producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time **(Pugh pa. [0044-0045]) [access to the patient's medical history… IMED database(s) may provide patent information to an emergency room that ends up saving the patient's life... IMED can be accessed in the event of an emergency without further "consent"** *(read authorization or permission)* **of the patient as they have authorized such access when they first created their patient file in the IMED system**: **note, "information that characterizes a group of individuals" has been interpreted as "patient's medical history"]** and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time **(Pugh pa. [0044-0045]) [access to the patient's medical history… IMED database(s) may provide patent information to an emergency room that ends up saving the patient's life... IMED can be accessed in the event of an emergency without further "consent"** *(read authorization or permission)* **of the patient as they have authorized such access when they first created their patient file in the IMED system: note, "information that characterizes a group of individuals" has been interpreted as "patient's medical history"]**

It is noted that **Pugh** does not appear explicitly disclose wherein the identity of the individuals is unattainable from the produced information.

However, **McLaughlin** discloses wherein the identity of the individuals is unattainable from the produced information **(McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]**

Pugh and **McLaughlin** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh** and **McLaughlin** before him or her to modify and configure the computing environment of **Pugh** to an electronic healthcare record

storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

6. **As to claim 2**, the combination of **Pugh-McLaughlin** teaches in which producing information that characterizes the group includes producing a request token for each individual included in the group **(McLaughlin pa. [00287]) [a plurality of patient tokens, each token associable with an individual patient]** See also**,** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh** and **McLaughlin** before him or her to modify and configure the computing environment of **Pugh** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

7. **As to claim 3**, the combination of **Pugh-McLaughlin** teaches in which producing the request token for each individual includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient…include biometric that to be uniquely identifiable with the patient… Information is stored in the memory of the token of an embodiment in encrypted**

format] See also**,** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh** and **McLaughlin** before him or her to modify and configure the computing environment of **Pugh** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

8. **As to claim 4**, the combination of **Pugh-McLaughlin** teaches in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match,** note: number can be viewed as token**]** See also**,** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh** and **McLaughlin** before him or her to modify and configure the computing environment of **Pugh** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

9. **As to claim 5**, the combination of **Pugh-McLaughlin** teaches in which the tokens associated with the information to be produced and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]** See also**,** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh** and **McLaughlin** before him or her to modify and configure the computing environment of **Pugh** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

10. **As to claim 6**, the combination of **Pugh-McLaughlin** in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]**

11. **As to claims 9, 18, and 27, Pugh** teaches in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated

with the individuals of the group **(Pugh pa. [0042]) [IMED capabilities may include entering, storing and retrieving the detail medical history of the patient]**

12. **As to claims 10-15**, claims 10-15 recite respectively substantial the same limitations as claims 1-6, but in the form of a system rather than a method, therefore, they are rejected under the same rationale.

13. **As to claims 19-24**, claims 19-24 recite respectively substantial the same limitations as claims 1-6, but in the form of a computer readable media rather than a method, therefore, they are rejected under the same rationale.

14. Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pugh: US 20060229919 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1.

15. **As to claims 7, 16, 25**, the combination of **Pugh-McLaughlin** does not appear explicitly disclose in which producing information that characterizes the group includes requesting a predefined portion of the information; in which the request represents a predefined portion of information to use for producing the information that characterizes the group; in which producing information that characterizes the group includes requesting a predefined portion of the information **(Scarlat, Fig. 3 pa. [0051]) [a significant portion of the required patient information is known to be pre-stored in**

the existing data stores 109]

Pugh, McLaughlin and **Scarlat** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh, McLaughlin** and **Scarlat** before him or her to modify and configure the computing environment of **Pugh-McLaughlin** to include parameters that would allow to analyze statistically of existing medical/healthcare databases to provide a patient and/or caregiver with an objective basis for making decisions between different treatments as taught by **Scarlat.** Thus, the motivation for doing so would have been to providing an evidenced based medical decision support system and associated method that utilizes existing database systems to automatically derive information through ad hoc query and statistical analysis whereby the derived information is fed back to a user in near real time **(Scarlat pa. [0006])**

16. **As to claims 8, 17, 26**, the combination of **Pugh-McLaughlin-Scarlat** discloses in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals **(Scarlat, Fig. 3 pa. [0057])** **[the results provided in the second query result, query result (2), also include, the number of patients in the sub-group]**

17. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pugh: US 20060229919 A1 in view of McLaughlin: US 20090024416 A1 in further view of GREEN, US 20110258000 A1.

18. **As to claim 28**, claim 28 recites substantially the same limitations as claim 1; therefore, it is rejected under the same rationale. In addition, the combination of **Pugh-McLaughlin** does not appear explicitly disclose de-identified healthcare data.

However, **Green** discloses de-identified healthcare data **(Green pa. [0060])** **[process includes querying de-identified patient diagnosis/medical history data and determining the number of patients with specific diagnoses]**

Pugh, McLaughlin and **GREEN** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pugh, McLaughlin** and **GREEN** before him or her to modify and configure the computing environment of **Pugh-McLaughlin** to include parameters that would allow to store data in relational databases, that data query to produce de-identified data sets as taught by **GREEN.** Thus, the motivation for doing so would have been to utilize the data captured in an integrated medical software system to conduct medical research, to maintain disease registries, to analyze the quality and safety of healthcare providers **(GREEN pa. [0002])**

19. **As to claim 29**, **Pugh** teaches wherein the healthcare information provided absent authorization from the group of individuals any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) (**Pugh pa. [00038]) [the present invention meets all HIPAA requirements ensuring the appropriate level of privacy and confidentiality related to the patient's medical information]**

20. **As to claim 30**, **Pugh** discloses wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals (**Pugh pa. [0017]) [The patient profile information may include the patient's name, address and telephone numbers, picture, the patient's contact information, insurance information, immunization records, birth certificate, information related to the person]**

Conclusion

21. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from

the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Primary Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2006/0229919	10-2006	Pugh, Timothy	705/003
*	B	US-2005/0261941	11-2005	Scarlat, Alexander	705/003
*	C	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	D	US-2011/0258000	10-2011	GREEN et al.	705/3
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014	08/25/2014				
	1	✓	✓	✓	✓	✓				
	2	✓	✓	✓	✓	✓				
	3	✓	✓	✓	✓	✓				
	4	✓	✓	✓	✓	✓				
	5	✓	✓	✓	✓	✓				
	6	✓	✓	✓	✓	✓				
	7	✓	✓	✓	✓	✓				
	8	✓	✓	✓	✓	✓				
	9	✓	✓	✓	✓	✓				
	10	✓	✓	✓	✓	✓				
	11	✓	✓	✓	✓	✓				
	12	✓	✓	✓	✓	✓				
	13	✓	✓	✓	✓	✓				
	14	✓	✓	✓	✓	✓				
	15	✓	✓	✓	✓	✓				
	16	✓	✓	✓	✓	✓				
	17	✓	✓	✓	✓	✓				
	18	✓	✓	✓	✓	✓				
	19	✓	✓	✓	✓	✓				
	20	✓	✓	✓	✓	✓				
	21	✓	✓	✓	✓	✓				
	22	✓	✓	✓	✓	✓				
	23	✓	✓	✓	✓	✓				
	24	✓	✓	✓	✓	✓				
	25	✓	✓	✓	✓	✓				
	26	✓	✓	✓	✓	✓				
	27	✓	✓	✓	✓	✓				
	28			✓	✓	✓				
	29			✓	✓	✓				
	30				✓	✓				

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED
380	28-30,255-283	12/12/2013	ED
713	150-154,160-167,189-193	12/12/2013	ED
705	3, 5	12/12/2013	ED
380	28-30,255-283	5/5/2014	ED
713	150-154,160-167,189-193	5/5/2014	ED
705	3, 5	5/5/2014	ED
380	28-30,255-283	8/25/2014	ED
713	150-154,160-167,189-193	8/25/2014	ED
705	3, 5	8/25/2014	ED

SEARCH NOTES		
Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	12/12/2013	ED

SEARCH NOTES		
Search Notes	**Date**	**Examiner**
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	5/5/2014	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	8/25/2014	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	**US Subclass / CPC Group**	**Date**	**Examiner**

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT;	OR	OFF	2012/05/30 15:30

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT;	OR	OFF	2012/05/30 17:58

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:04

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual)	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:17

		same (medical near5 record)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5	US-PGPUB; USPAT;	OR	OFF	2012/05/31 17:43

		group)	USOCR; FPRS; EPO; JPO; IBM_TDB			
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT;	OR	OFF	2013/12/06 10:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT;	OR	OFF	2013/12/06 11:23

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5	US-PGPUB; USPAT;	OR	OFF	2013/12/12 11:58

		authoriz$5	USOCR; FPRS; EPO; JPO; IBM_TDB			
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT;	OR	OFF	2013/12/12 12:48

			USOCR; FPRS; EPO; JPO; IBM_TDB			
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47
S94	2	("20030037054").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 13:40
S95	1	("6988075").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 14:30
S96	3	(("20110225007") or ("20090070146")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:01
S97	5248	(Extending adj the adj Health adj Insurance adj Portability adj Accountability adj Act) (HIPAA)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:05
S98	209	(((information data record)) same without near5 (patient individual) near5 authoriz$5)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:06
S99	209	(((information data record)) same without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:07

			JPO; IBM_TDB			
S100	264	(((information data record)) same without near5 (patient individual group) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S101	52	S97 and S100	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:07
S102	43	S101 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:08
S103	2934	705/1,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S104	19817	705/1,2,3,4,5.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:37
S105	3	(Internet adj medical adj information adj system (IMED)) same (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:39
S106	1594	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:41
S107	7891	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S108	7	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same without near5 (permision authoriz$5))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:43
S109	6	S108 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2014/08/22 15:43

			JPO; IBM_TDB			
S110	146	S104 and (access$5 near5 (patient individual group) near5 medical near5 (information data record) same emergency)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S111	123	S110 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:45
S112	32	S97 and S111	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 15:48
S113	2	S112 and (without near5 (patient individual) near5 (authoriz$5 permision))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2014/08/22 16:07

8/25/2014 10:50:31 AM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2007/0043594	02/2007	Lavergne			
	2	2010/0162355	06/2010	Zimmerman, et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	3							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	4	

Examiner Signature /Evans Desrosiers/	Date Considered 08/25/2014
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602

Title : DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF MAY 19, 2014

Please consider the following reply.

List of claims (replacing prior versions).

1. (Previously Presented) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Previously Presented) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Previously Presented) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

28. (Previously Presented) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information;

producing, by a processor, individual identifiers, wherein the identity of the individuals is unattainable from the individual identifiers, each individual identifier being associated with a corresponding individual identifier in a set of de-identified healthcare data, and each individual identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing, absent authorization from the group of individuals at any time, the requested healthcare information by identifying the individual identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced individual identifiers, wherein the produced healthcare information is absent personally identifiable information; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals at any time.

29. (Previously Presented) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (Previously Presented) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

REMARKS

The undersigned representative thanks Examiners Bechtel and Patel for the courtesy of the telephonic interview held on July 17, 2014 with the undersigned representative and Natalie Galley.

Examiner Bechtel suggested that the feature "absent authorization from the group of individuals at any time" could indicate a situation including pre-authorization and refer to a subsequent point of time in which authorization was not required. Examiner Bechtel also indicated that "the identity of the individuals is unattainable from the produced information" may lack enablement as he does not believe that it is possible to ensure that the identity of individuals is unattainable. The interview also included a discussion of new references that were not cited in the current action. Examiner Bechtel was understood to allege that the previously unknown references, Theis (U.S. Patent Number 2011/0225007) and Haider (U.S. Patent Number 2009/0070146), show that claim 1 reads on the implementation expressly permitted by HIPAA. Further, Examiner Bechtel suggested that someone practicing the invention had implicit authorization under HIPAA. Applicant's representatives did not concede any of the above to be true, but agreed to consider Theis and Haider when responding to the office action.

The interview included only a brief discussion of the rejections of record under 35 U.S.C. § 103(a). Applicant's representatives pointed out that all limitations of independent claim 1 are not found or made obvious in the art of record, i.e., Pollanz, McLaughlin, and Scarlat. Applicants also pointed out that the office action did not appear to consider the amendment filed in response to the previous action. Rather, the office action merely reiterated the previous rejection, including rejections over Schoenberg, a reference which had been removed two office actions previously.

Examiner Patel agreed to remove the finality of the current office action.

A second interview also took place on July 24, 2014 with the undersigned representative and Examiners Desrosiers and Patel. Examiner Desrosier, who initiated the discussion with a telephone call, stated that he would not remove the finality of the current action. Given the two different positions from the Office, the undersigned requested that Examiner Patel join the

discussion, which he did. Examiner Patel stated that upon receiving a reply to the current action, a non-final office action would be prepared and sent. Examiner Patel also stated that a request for continued examination would not need to be filed. The undersigned expressed concern, but Examiner Patel assured that a non-final response would be prepared and mailed in a timely manner so such a request would not be needed.

Claims 1-30 are pending in this application, with claims 1, 10, 19, and 28 being independent. Favorable reconsideration is respectfully requested in view of the following amendments and comments of the Applicant, which are preceded by related comments of the Examiner in small bold type.

Claim Rejections – 35 USC §103

Claims 1-6, 9-15, 18-24, 27 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 .

Independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

Pollanz is understood to describe a personal medical information storage and analysis system in communication with a secure patient database and a patient with secure personal medical information (please see abstract). In Pollanz's system, the patient has control over his medical information and must grant access to a third person such as a medical provider before any of his information can be viewed.

As pointed out on p. 14 of the Office Action, Pollanz states that a healthcare provider may at one point access personal medical information that they individually provided to the patient database "without further authorization from the patient" (please see abstract). Pollanz's requirement that *further* authorization is not required clearly indicates that authorization for the healthcare provider to access the patient's personal medical information was at some point required. That is, no *further* authorization means authorization is not needed in addition to the

authorization given before. Pollanz is clear that no medical service provider "has any right to view, add or delete, any data unless the patient grants his/her consent" (please see paragraph [0119]). Thus, Pollanz does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1. Pollanz appears to suggest the opposite.

Additionally, McLaughlin is not understood to remedy these deficiencies of Pollanz.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Pollanz and McLaughlin. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1.

Scarlat is not understood to remedy the foregoing deficiencies of Pollanz and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). Similar to Pollanz and McLaughlin, Scarlat does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Pollanz, McLaughlin and Scarlat. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 7,

8, 16, 17, 25, and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

Claims 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of GREEN, US 20110258000 A1.

Similarly, Pollanz, McLaughlin and Green are not understood to disclose or suggest receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information, and producing, absent authorization from the group of individuals at any time, the requested healthcare information, and providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals at any time. Newly added dependent claim 30 partakes of the novelty of parent independent claim 28 and, as such, has not been addressed specifically herein.

Regarding claim 29, the Examiner cites Pollanz, paragraph [0003], which merely mentions to the Health Insurance Portability and Accountability Act (HIPAA). Theis and Haider, mentioned in the first interview, are understood to state rules and requirements of HIPAA. For example, Haider states that under HIPAA, information "may be disclosed to others for treatment, payment and health care operations" without the individual's express permission (paragraph [0025]) and Theis also states "patients do not control their information inside that 'HIPAA triangle'" (paragraph [0025]). However these are statements of what is acceptable under HIPAA, and Pollanz, Theis and Haider do not disclose or suggest a computer-implemented method wherein the healthcare information provided absent authorization from the group of individuals is in conformity with HIPAA, as recited in claim 29.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the

amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

No fees are believed due at this time. Please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 19 August 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23232077.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor	:	Andrew L. Paris III	Art Unit	:	2491
Serial No.	:	12/827,745	Examiner	:	Evans Desrosiers
Filed	:	June 30, 2010	Conf. No.	:	5602
Title	:	DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING			

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. The fees in the amount of $90 in payment of the late submission fee of 37 CFR §1.17(p) are being paid concurrently herewith. In addition, please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 19 August 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 956-5911
Facsimile: (877) 769-7945

23278047.doc

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2007/0043594	02/2007	Lavergne			
	2	2010/0162355	06/2010	Zimmerman, et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	3							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	4	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Electronic Acknowledgement Receipt

EFS ID:	19899561
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	19-AUG-2014
Filing Date:	30-JUN-2010
Time Stamp:	11:37:54
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2001Resp.pdf	131149 d79c94e04cdbb3f2b968f3e59f4204456800dad1	yes	11

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	11

Warnings:					
Information:					
2		2001IDS.pdf	119602 0b581a05542928f7b0627d2fbf697097d88dbf67	yes	2

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Transmittal Letter	1	1
	Information Disclosure Statement (IDS) Form (SB08)	2	2

Warnings:	
Information:	
Total Files Size (in bytes):	250751

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 12/827,745	Filing Date 06/30/2010	☐ To be Mailed

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **08/19/2014**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 30	Minus	** 30	= 0	X $40 =	0
Independent (37 CFR 1.16(h))	* 4	Minus	***4	= 0	X $210 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	0

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/LINDA A. WASHINGTON/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 07/23/2014
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
07/23/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	Kevin Bechtel	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *Kevin Bechtel (Examiner AU 2491)*.

(2) *Ashokkumar Patel (SPE AU 2491)*.

(3) *Jeffery Barclay (Reg #48,950)*.

(4) *Natalie Galley*.

Date of Interview: *17 July 2014*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☒112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1*.

Identification of prior art discussed: *See Continuation Sheet*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

See Continuation Sheet.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/Kevin Bechtel/ Examiner, Art Unit 2491	/ASHOK PATEL/ Supervisory Patent Examiner, Art Unit 2491

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Continuation of Identification of prior art discussed: McLaughlin et al. (US Pre-Grant Publication No. 20090024416, hereinafter "McLaughlin"), Pollanz (US Pre-Grant Publication No. 20060184524, hereinafter "Pollanz"), Theis (US Pre-Grant Publication No. 20110225007, hereinafter "Theis"), and Haider et al. (US Pre-Grant Publication No. 20090070146, hereinafter "Haider").

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The Examiners and Applicant's Representatives discussed the prior art in view of the art of record. In particular, the Examiners noted that it appeared the claims still read on the art of record, as "absent authorization from the group of individuals at any time" still reads on a disclosure of pre-authorization, just so long as there is a point of time in which authorization is not requested. That is, there is a difference between "there is no time at which authorization is provided" versus "there exists any time at which authorization is not given". It's a bit of semantics as to how "any" is used. The Examiner noted, however, that semantics aside, even if the claims were given the narrow interpretation intended by Applicant, the independent claim appears to read on the implementation expressly permitted by the HIPPA law, as evidenced by Theis [0025] and Haider [0008]. Further, the Examiner noted that the limitation "wherein the identity of the individuals is unattainable from the produced information" is a functional claim limitation that may lack enablement, as one generally cannot ensure that anonymized information is cannot be reversed to reveal identity of the individuals, rather, one is limited to taking specific steps to reasonably ensure that data cannot be de-anonymized, such as recognized by the "Safe Harbor" clause of HIPAA. Also, the Examiner noted that technically, it seems reasonable to argue that health care providers obtain authorization to release anonymized information from a user of health care, even if only implicitly under HIPAA. That is, that even someone attempting to practice the claimed invention would have implicitly received authorization from HIPAA, just as a user using Google gives implicit consent to their data being collected, whether they like it or not. Applicant's Representatives indicated that such would be considered in their next response.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 05/19/2014
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
05/19/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *03/17/2014*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-30* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-30* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/30/2010* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. Claims 1-30 remain for examination. Claims 1, 10, 19, 20 and 29 have been amended. Claim 30 has been added. Applicant's arguments filed on 03/17/2014 have been fully considered but they are not persuasive. The rejections are maintained and incorporated by reference the last Office action on 12/18/2013. Accordingly, this action has been made final.

Examiner's Note

2. Examiner has cited particular columns and line numbers in the references as applied to the claims for the convenience of the applicant. Although the specified citations are representative of the teachings of the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested from the applicant in preparing responses, to fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the Examiner.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the

subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

4. Claims 1-6, 9-15, 18-24, 27 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1.

5. **As to claim 1**, **Pollanz** teaches a computer-implemented method comprising: producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time (**Pollanz, abstract pa. [0136], claim 1) [The system still further includes the secure patient database being accessible by healthcare providers for the personal medical information that they individually provided to the at least one secure patient database without further authorization from the patient].**

It is noted that **Pollanz** does not appear explicitly disclose wherein the identity of the individuals is unattainable from the produced information.

However, **McLaughlin** discloses wherein the identity of the individuals is unattainable from the produced information **(McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also,**

see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]

Pollanz and **McLaughlin** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz** and **McLaughlin** before him or her to modify and configure the computing environment of **Pollanz** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

6. **As to claim 2**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes producing a request token for each individual included in the group **(McLaughlin pa. [00287]) [a plurality of patient tokens, each token associable with an individual patient]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy,

and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

7. **As to claim 3**, the combination of **Schoenberg-McLaughlin** teaches in which producing the request token for each individual includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient…include biometric that to be uniquely identifiable with the patient… Information is stored in the memory of the token of an embodiment in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

8. **As to claim 4**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced **(McLaughlin pa. [0024]) [verifies the patient's identity by obtaining a biometric from the patient** *(note: the biometric is in token format)* **and comparing it to "corresponding information"** *(read token)* **stored in the token memory] [0222] [The matching server**

generates the identification number from the extracted finger minutiae template and compares the identification number to the stored number] Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

9. **As to claim 5**, the combination of **Schoenberg-McLaughlin** teaches in which the tokens associated with the information to be produced and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

10. **As to claim 6**, the combination of **Schoenberg-McLaughlin** in which producing information that characterizes the group includes determining if the comparison

provides at least a minimum number of matches **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

11. **As to claims 9, 18, and 27,** **Pollanz** teaches in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated with the individuals of the group (**Pollanz pa. [0056]) [secure patient database 112 in which secure personal medical portals (e.g., databases) may be created and maintained for individual patients who have subscribed to the service, and to an Internet pharmacy 114, which may include a prescription program]**

12. **As to claims 10-15**, claims 10-15 recite respectively substantial the same limitations as claims 1-6, but in the form of a system rather than a method, therefore, they are rejected under the same rationale.

13. **As to claims 19-24**, claims 19-24 recite respectively substantial the same limitations as claims 1-6, but in the form of a computer readable media rather than a method, therefore, they are rejected under the same rationale.

14. Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1.

15. **As to claims 7, 16, 25**, the combination of **Pollanz-McLaughlin** does not appear explicitly disclose in which producing information that characterizes the group includes requesting a predefined portion of the information; in which the request represents a predefined portion of information to use for producing the information that characterizes the group; in which producing information that characterizes the group includes requesting a predefined portion of the information **(Scarlat, Fig. 3 pa. [0051]) [a significant portion of the required patient information is known to be pre-stored in the existing data stores 109]**

Pollanz, McLaughlin and **Scarlat** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz, McLaughlin** and **Scarlat** before him or her to modify and configure the computing environment of **Pollanz-McLaughlin** to include parameters that would allow to analyze statistically of existing medical/healthcare databases to provide a patient and/or caregiver with an objective

basis for making decisions between different treatments as taught by **Scarlat.** Thus, the motivation for doing so would have been to providing an evidenced based medical decision support system and associated method that utilizes existing database systems to automatically derive information through ad hoc query and statistical analysis whereby the derived information is fed back to a user in near real time **(Scarlat pa. [0006])**

16. **As to claims 8, 17, 26**, the combination of **Pollanz-McLaughlin-Scarlat** discloses in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals **(Scarlat, Fig. 3 pa. [0057]) [the results provided in the second query result, query result (2), also include, the number of patients in the sub-group]**

17. Claims 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of GREEN, US 20110258000 A1.

18. **As to claim 28**, claim 28 recites substantially the same limitations as claim 1; therefore, it is rejected under the same rationale. In addition, the combination of **Pollanz-McLaughlin** does not appear explicitly disclose de-identified healthcare data.

However, **Green** discloses de-identified healthcare data **(Green pa. [0060]) [process includes querying de-identified patient diagnosis/medical history data and determining the number of patients with specific diagnoses]**

Pollanz, McLaughlin and **GREEN** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz, McLaughlin** and **GREEN** before him or her to modify and configure the computing environment of **Pollanz-McLaughlin** to include parameters that would allow to store data in relational databases, that data query to produce de-identified data sets as taught by **GREEN.** Thus, the motivation for doing so would have been to utilize the data captured in an integrated medical software system to conduct medical research, to maintain disease registries, to analyze the quality and safety of healthcare providers **(GREEN pa. [0002])**

19. **As to claim 29**, **Pollanz** teaches wherein the healthcare information provided absent authorization from the group of individuals any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) (**Pollanz pa. [0003])** **[executive laws that deal with the use of medical data in accordance with the provisions of the Patient's Bill of Rights Act, are summarized under the Health Insurance Portability and Accountability Act of 1996 (HIPAA)]**

20. **As to claim 30**, the combination of **Pollanz, McLaughlin** and **GREEN** discloses wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals (**Pollanz pa. [0060]) [provides a**

secure personal health record database with access controlled by the user (i.e., patient), but accessible by healthcare providers to enter and read information, if authorized by the user]

Response to Arguments

21. Argument 1

a. Amended independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time. Pollanz is understood to describe a personal medical information storage and analysis system in communication with a secure patient database and a patient with secure personal medical information (please see abstract). In Pollanz's system, the patient has control over his medical information and must grant access to a third person such as a medical provider before any of his information can be viewed. For example, Pollanz states…

Pollanz states that a healthcare provider may at one point access personal medical information that they individually provided to the patient database "without further authorization from the patient" (please see abstract, emphasis added). Pollanz's requirement that further authorization is not required clearly indicates that authorization

for the healthcare provider to access the patient's personal medical information was at some point required. Pollanz is clear that no medical service provider "has any fight to view, add or delete, any data unless the patient grants his/her consent" (please see paragraph [0119]). Thus, Pollanz does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1. Pollanz appears to suggest the opposite. Further, Pollanz allows access only following authorization being originally granted by the patient. Thus, Pollanz does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1.

Additionally, McLaughlin is not understood to remedy these deficiencies of Pollanz. For at least these reasons, amended independent claim 1 is believed to be patentable over any combination of Pollanz and McLaughlin. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27

respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein. (*Applicant's remarks pages 7-8)*

Examiner's response 1.a:

In response to applicant's argument, Examiner respectfully disagrees with the Applicant for at least the following reasons:

First, claims are to be given their broadest reasonable interpretation during prosecution, and the scope of a claim cannot be narrowed by reading disclosed limitations into the claim. See In re Morris, 127 F.3d 1048, 1054, 44 USPQ2D 1023, 1027 (Fed. Cir. 1997); In re Zletz, 893 F.2d 319, 321, 13 USPQ2D 1320, 1322 (Fed. Cir. 1989); In re Prater, 415 F.2d 1393, 1404, 162 USPQ 541,550 (CCPA 1969). In addition, it does not require that a reference "teach" what an appellant's disclosure teaches. Assuming that reference is properly "prior art,'" it is only necessary that the claims "read on" something disclosed in the reference, i.e., all limitations of the claim are found in the reference, or "fully met" by it. Kalman v. Kimberly-Clark Corp., 713 F.2d 760, 772, 218 USPQ 781,789 (Fed. Cir. 1983).

Secondly, the combination of Pollanz and McLaughlin fairly discloses the claimed limitations " producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time (Pollanz, abstract pa. [0136], claim 1) [The system still further includes the secure patient database being accessible by healthcare

providers for the personal medical information that they individually provided to the at least one secure patient database without further authorization from the patient]. In addition, McLaughlin discloses wherein the identity of the individuals is unattainable from the produced information (McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity".] Therefore, the Applicant's arguments are moot.

b. Scarlat is not understood to remedy the foregoing deficiencies of Pollanz and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). However, the Applicant submits that similar to Pollanz and McLaughlin, Scarlat does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1. For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Pollanz, McLaughlin and Scarlat. Similarly, amended independent claims 10 and 19 are also believed to be

allowable for at least the same reasons noted above. The dependent claims 7, 8, 16, 17, 25, and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein. . (*Applicant's remarks page 9)*

Examiner's response 1.b:

In response to applicant's argument, it is respectfully submitted that these arguments have been previously addressed in **Examiner's response 1.a**.

c. Similarly, Pollanz, McLaughlin and Green are not understood to disclose or suggest receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information, and producing, absent authorization from the group of individuals at any time, the requested healthcare information, and providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals at any time. Newly added dependent claim 30 partakes of the novelty of parent independent claim 28 and, as such, has not been addressed specifically herein.

Regarding claim 29, the Examiner cites Pollanz, in particular paragraphs [0003] and [0004]. These paragraphs appear to merely make reference to the Health Insurance Portability and Accountability Act (HIPAA). Thus, Pollanz does not disclose or suggest a computer- implemented method wherein the healthcare information provided absent authorization from the group of individuals is in conformity with HIPAA. Although not cited by the Examiner directly, Green and McLaughlin also refer to HIPAA but likewise do not disclose that the healthcare information provided absent authorization

from the group of individuals is in conformity with HIPAA. For example, McLaughlin includes a feature that the "Enrollment Specialist confirms patient signed the HIPAA consent" (see, e.g., paragraph [0191], emphasis added) while Green includes a feature wherein to "address HIPAA's privacy regulations, each system of the IPI 100 may include functionality for consent tracking and disclosure logging" (see, e.g., paragraph [0050], emphasis added). Therefore none of Pollanz, Green, and McLaughlin is understood to disclose or suggest a computer-implemented method wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with HIPAA, as required by claim 29. (*Applicant's remarks pages 9-10)*

Examiner's response 1.c:

In response to applicant's argument, it is respectfully submitted that the limitations of claim 29 have been clearly addressed. See wherein the healthcare information provided absent authorization from the group of individuals any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) (**Pollanz pa. [0003]) [executive laws that deal with the use of medical data in accordance with the provisions of the Patient's Bill of Rights Act, are summarized under the Health Insurance Portability and Accountability Act of 1996 (HIPAA)]**

Conclusion

22. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final

action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2006/0184524	08-2006	Pollanz, Gunter	707/006
*	B	US-2005/0261941	11-2005	Scarlat, Alexander	705/003
*	C	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	D	US-2011/0258000	10-2011	GREEN et al.	705/3
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013	05/05/2014					
	1	✓	✓	✓	✓					
	2	✓	✓	✓	✓					
	3	✓	✓	✓	✓					
	4	✓	✓	✓	✓					
	5	✓	✓	✓	✓					
	6	✓	✓	✓	✓					
	7	✓	✓	✓	✓					
	8	✓	✓	✓	✓					
	9	✓	✓	✓	✓					
	10	✓	✓	✓	✓					
	11	✓	✓	✓	✓					
	12	✓	✓	✓	✓					
	13	✓	✓	✓	✓					
	14	✓	✓	✓	✓					
	15	✓	✓	✓	✓					
	16	✓	✓	✓	✓					
	17	✓	✓	✓	✓					
	18	✓	✓	✓	✓					
	19	✓	✓	✓	✓					
	20	✓	✓	✓	✓					
	21	✓	✓	✓	✓					
	22	✓	✓	✓	✓					
	23	✓	✓	✓	✓					
	24	✓	✓	✓	✓					
	25	✓	✓	✓	✓					
	26	✓	✓	✓	✓					
	27	✓	✓	✓	✓					
	28			✓	✓					
	29			✓	✓					
	30				✓					

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2004/0143403	07/2004	Brandon et al.			
	2	2006/0020611	01/2006	Gilbert et al.			
	3	2008/0133273	06/2008	Marshall			
	4	2009/0287502	11/2009	Roberts et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	5							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	6	

Examiner Signature	Date Considered
/Evans Desrosiers/	05/12/2014

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.D./

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED
380	28-30,255-283	12/12/2013	ED
713	150-154,160-167,189-193	12/12/2013	ED
705	3, 5	12/12/2013	ED
380	28-30,255-283	5/5/2014	ED
713	150-154,160-167,189-193	5/5/2014	ED
705	3, 5	5/5/2014	ED

SEARCH NOTES		
Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	12/12/2013	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	5/5/2014	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/05 11:08
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30

S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24

S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10

S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42

S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07

S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51
S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:23

S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32
S71	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
S72	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
S73	1	S71 and S72	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
S74	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S75	0	S71 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S76	35	S74 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
S77	0	S71 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S78	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
S79	0	S78 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S80	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
S81	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06

S82	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S83	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
S84	167	S81 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S85	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
S86	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S87	0	S86 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
S88	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S89	8	S86 and S88	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
S90	8	S89 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S91	4	(("2007033405") or ("2003123668") or ("2001046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S92	3	(("20070033405") or ("20030123668") or ("20010046291")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 15:31
S93	4	US-20040143403-$.DID. OR US-20060020611-$.DID. OR US-20080133273-$.DID. OR US-20090287502-$.DID.	US-PGPUB; USPAT	OR	OFF	2014/05/02 10:47

5/5/2014 11:08:30 AM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Substitute Disclosure Form	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 25412-0002001	Application No. 12/827,745
Information Disclosure Statement by Applicant (Use several sheets if necessary)		First Named Inventor Andrew L. Paris III	
(37 CFR §1.98(b))		Filing Date June 30, 2010	Group Art Unit 2491

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2004/0143403	07/2004	Brandon et al.			
	2	2006/0020611	01/2006	Gilbert et al.			
	3	2008/0133273	06/2008	Marshall			
	4	2009/0287502	11/2009	Roberts et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	5							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	6	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Submission- Information Disclosure Stmt	2806	1	90	90
		Total in USD ($)		**90**

Electronic Acknowledgement Receipt

EFS ID:	18659032
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	03-APR-2014
Filing Date:	30-JUN-2010
Time Stamp:	09:15:27
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$90
RAM confirmation Number	9291
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Exhibit 1002

1		2001IDS.pdf	119721 09988dd935c7180121f2b79525d1687efdb47d47	yes	2

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Transmittal Letter	1	1
Information Disclosure Statement (IDS) Form (SB08)	2	2

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	30017 777e2bec7b972f4b58e6cf1eeeeb19879b9b214b	no	2

Warnings:

Information:

Total Files Size (in bytes):	149738

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Please consider the references listed on the enclosed PTO-SB-08 or Disclosure Form. Foreign patent documents and non-patent literature are enclosed; cited U.S. patents and patent application publications will be provided on request.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. The fees in the amount of $90 in payment of the late submission fee of 37 CFR §1.17(p) are being paid concurrently herewith. In addition, please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 3 April 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23199531.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF DECEMBER 18, 2013

Please consider the following reply.

List of claims (replacing prior versions).

1. (Currently Amended) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Currently Amended) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

28. (Currently Amended) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information;

producing, by a processor, individual identifiers, wherein the identity of the individuals is unattainable from the individual identifiers, each individual identifier being associated with a corresponding individual identifier in a set of de-identified healthcare data, and each individual identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing, absent authorization from the group of individuals at any time, the requested healthcare information by identifying the individual identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced individual identifiers, wherein the produced healthcare information is absent personally identifiable information; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals at any time.

29. (Currently Amended) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

30. (New) The computer-implemented method of claim 28, wherein receiving a request for healthcare information that characterizes a group of individuals from healthcare data includes receiving personally identifiable information associated with members of the group of individuals.

REMARKS

The Applicant appreciates and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application on 7 January 2014 with the Applicant, Mr. Andrew L. Paris III, and the Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Applicant's representatives have reviewed the Examiner's interview summary mailed January 10, 2014. Along with discussing the current action, the pending claims and art references cited in the action were also discussed.

Claims 1-30 are pending in this application, with claims 1, 10, 19, and 28 being independent and claim 30 newly added. Favorable reconsideration is respectfully requested in view of the following amendments and comments of the Applicant, which are preceded by related comments of the Examiner in small bold type.

Claim Rejections – 35 USC § 103

Claims 1-6, 9-15, 18-24, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 .

Amended independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals at any time.

Pollanz is understood to describe a personal medical information storage and analysis system in communication with a secure patient database and a patient with secure personal medical information (please see abstract). In Pollanz's system, the patient has control over his medical information and must grant access to a third person such as a medical provider before any of his information can be viewed. For example, Pollanz states:

> "in the personal medical portal system the ultimate owner and exclusive authority over an individual's (patient's) personal medical information is the individual (patient). Thus, it is the *exclusive right of a subscribing patient to decide to whom he/she is granting (full or partial) access to his/her medical information*. The

> system may implement this function with an Internet-based Access Authorization Tool (AAT) that allows the patient to initiate and grant access rights to medical partners. In general, *no partner will be able to access all or any part of an individual's PMP without the explicit access authorization granted by the patient* through his/her AAT." (please see paragraph [0061], emphasis added).

Pollanz states that a healthcare provider may at one point access personal medical information that they individually provided to the patient database "without *further* authorization from the patient" (please see abstract, emphasis added). Pollanz's requirement that *further* authorization is not required clearly indicates that authorization for the healthcare provider to access the patient's personal medical information was at some point required. Pollanz is clear that no medical service provider "has any right to view, add or delete, any data unless the patient grants his/her consent" (please see paragraph [0119]). Thus, Pollanz does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1. Pollanz appears to suggest the opposite. Further, Pollanz allows access only following authorization being originally granted by the patient. Thus, Pollanz does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1.

Additionally, McLaughlin is not understood to remedy these deficiencies of Pollanz.

For at least these reasons, amended independent claim 1 is believed to be patentable over any combination of Pollanz and McLaughlin. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1.

Scarlat is not understood to remedy the foregoing deficiencies of Pollanz and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). However, the Applicant submits that similar to Pollanz and McLaughlin, Scarlat does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals at any time, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals at any time, as required by amended independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Pollanz, McLaughlin and Scarlat. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 7, 8, 16, 17, 25, and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

Claims 28-29 are rejected under 35 U.S.C. 1 03(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of GREEN, US 20110258000 A1.

Similarly, Pollanz, McLaughlin and Green are not understood to disclose or suggest receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information, and producing, absent authorization from the group of individuals at any time, the requested healthcare information, and providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals at any time. Newly added dependent claim 30 partakes of the novelty of parent independent claim 28 and, as such, has not been addressed specifically herein.

Regarding claim 29, the Examiner cites Pollanz, in particular paragraphs [0003] and [0004]. These paragraphs appear to merely make reference to the Health Insurance Portability and Accountability Act (HIPAA). Thus, Pollanz does not disclose or suggest a computer-implemented method wherein the healthcare information provided absent authorization from the group of individuals is in conformity with HIPAA. Although not cited by the Examiner directly, Green and McLaughlin also refer to HIPAA but likewise do not disclose that the healthcare information provided absent authorization from the group of individuals is in conformity with HIPAA. For example, McLaughlin includes a feature that the "Enrollment Specialist confirms patient *signed the HIPAA consent*" (see, e.g., paragraph [0191], emphasis added) while Green includes a feature wherein to "address HIPAA's privacy regulations, each system of the IPI 100 may include functionality *for consent tracking* and disclosure logging" (see, e.g., paragraph [0050], emphasis added). Therefore none of Pollanz, Green, and McLaughlin is understood to disclose or suggest a computer-implemented method wherein the healthcare information provided absent authorization from the group of individuals at any time is in conformity with HIPAA, as required by claim 29.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

The fee in the amount of $40 for the excess claim fee is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account Authorization. Please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 17 March 2014

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23139547.doc

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Claims in excess of 20	2202	1	40	40
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
		Total in USD ($)		**40**

Electronic Acknowledgement Receipt

EFS ID:	18489326
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	17-MAR-2014
Filing Date:	30-JUN-2010
Time Stamp:	10:39:51
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$40
RAM confirmation Number	13221
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Exhibit 1002

1		2001.pdf	138814 ff37b4b37c7a978a182d141ab4c660bdc99d19f3	yes	11

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Amendment/Req. Reconsideration-After Non-Final Reject	1	1
Claims	2	6
Applicant Arguments/Remarks Made in an Amendment	7	11

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	29774 e23dba4020f6612394cb758757faa22b724d3462	no	2

Warnings:

Information:

Total Files Size (in bytes):	168588

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 12/827,745	Filing Date 06/30/2010	☐ To be Mailed

ENTITY: ☐ LARGE ☒ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT

03/17/2014	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 30	Minus	** 29	= 1	X $40 =	40
Independent (37 CFR 1.16(h))	* 4	Minus	***4	= 0	X $210 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	40

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

LIE
/DESHONNE T. MARTINO/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 01/10/2014

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
01/10/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(2) *Andrew L. Paris III*.

(3) *Jeffrey J, Barclay*.

(4) *Natalie Galley*.

Date of Interview: *07 January 2014*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☐ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☐112 ☐102 ☒103 ☒Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1 and 28*.

Identification of prior art discussed: *Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1, GREEN, US 20110258000 A1*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art and potential amendments to overcome the prior arts cited. Claims1and 28 were discussed. Applicant provided the analysis of the claim. Applicant argued that Pollanz reference does not teach the features of "characteristics of the individuals" Examiner pointed out paragraph [0133] of Pollanz and explained to Applicant representative how these feartures have been interpreted. Also, Claim 28 was discussed, Applicant argued that the Green reference does not have the word identifier, Examiner replied how a system can manage individuals or patients without proper identifier? In addition, "absent authorization" was discussed, Applicant agreed to make these features clear. Finally, Applicant will submit an official amendment. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Examiner, Art Unit 2491	

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 12/18/2013
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
12/18/2013	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No. 12/827,745	Applicant(s) PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *05/06/2013*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *1-29* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-29* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/30/2010* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions. This communication is in respond to applicant's request for continued examination filed on 05/06/2013. Claims 1-29 are pending.

Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 05/06/2013 has been entered.

Examiner's Note

3. Examiner has cited particular columns and line numbers in the references as applied to the claims above for the convenience of the applicant. Although the specified citations are representative of the teachings of the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested from the applicant in preparing responses, to fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the Examiner.

Response to Arguments

4. Applicant's arguments with respect to amended claims have been fully considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

6. Claims 1-6, 9-15, 18-24, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1.

7. **As to claim 1**, **Pollanz** teaches computer-implemented method comprising: producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals; and providing the produced information to report the characteristics of the group absent authorization from the group of individuals (**Pollanz, abstract pa. [0136], claim 1) [The system still further includes the secure patient**

database being accessible by healthcare providers for the personal medical information that they individually provided to the at least one secure patient database without further authorization from the patient].

It is noted that **Pollanz** does not appear explicitly disclose wherein the identity of the individuals is unattainable from the produced information.

However, **McLaughlin** discloses wherein the identity of the individuals is unattainable from the produced information **(McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]**

Pollanz and **McLaughlin** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz** and **McLaughlin** before him or her to modify and configure the computing environment of **Pollanz** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

8. **As to claim 2**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes producing a request token for each individual included in the group **(McLaughlin pa. [00287]) [a plurality of patient tokens, each token associable with an individual patient]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

9. **As to claim 3**, the combination of **Schoenberg-McLaughlin** teaches in which producing the request token for each individual includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient…include biometric that to be uniquely identifiable with the patient… Information is stored in the memory of the token of an embodiment in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so

would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

10. **As to claim 4**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced **(McLaughlin pa. [0024]) [verifies the patient's identity by obtaining a biometric from the patient** *(note: the biometric is in token format)* **and comparing it to "corresponding information"** *(read token)* **stored in the token memory] [0222] [The matching server generates the identification number from the extracted finger minutiae template and compares the identification number to the stored number]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

11. **As to claim 5**, the combination of **Schoenberg-McLaughlin** teaches in which the tokens associated with the information to be produced and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]** Therefore,

it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

12. **As to claim 6**, the combination of **Schoenberg-McLaughlin** in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches **(McLaughlin pa. [0222-0223])** **[matching server compares the identification number to the stored number and generates a token in response to the match]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

13. **As to claims 9, 18, and 27, Pollanz** teaches in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated with the individuals of the group; in which the private data represents medical related information associated with the individuals of the group (**Pollanz pa. [0056]) [secure patient database 112 in which secure personal medical portals (e.g., databases) may be created and maintained for individual patients who have subscribed to the service, and to an Internet pharmacy 114, which may include a prescription program]**

14. **As to claims 10-15**, claims 10-15 recite respectively substantial the same limitations as claims 1-6, but in the form of a system rather than a method, therefore, they are rejected under the same rationale.

15. **As to claims 19-24**, claims 19-24 recite respectively substantial the same limitations as claims 1-6, but in the form of a computer readable media rather than a method, therefore, they are rejected under the same rationale.

16. Claims 7-8, 16-17, and 25-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1.

17. **As to claims 7, 16, 25**, the combination of **Pollanz-McLaughlin** does not appear explicitly disclose in which producing information that characterizes the group includes requesting a predefined portion of the information; in which the request represents a predefined portion of information to use for producing the information that characterizes the group; in which producing information that characterizes the group includes requesting a predefined portion of the information **(Scarlat, Fig. 3 pa. [0051]) [a significant portion of the required patient information is known to be pre-stored in the existing data stores 109]**

Pollanz, McLaughlin and **Scarlat** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz, McLaughlin** and **Scarlat** before him or her to modify and configure the computing environment of **Pollanz-McLaughlin** to include parameters that would allow to analyze statistically of existing medical/healthcare databases to provide a patient and/or caregiver with an objective basis for making decisions between different treatments as taught by **Scarlat.** Thus, the motivation for doing so would have been to providing an evidenced based medical decision support system and associated method that utilizes existing database systems to automatically derive information through ad hoc query and statistical analysis whereby the derived information is fed back to a user in near real time **(Scarlat pa. [0006])**

18. **As to claims 8, 17, 26**, the combination of **Pollanz-McLaughlin-Scarlat** discloses in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals **(Scarlat, Fig. 3 pa. [0057]) [the results provided in the second query result, query result (2), also include, the number of patients in the sub-group]**

19. Claims 28-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pollanz: US 20060184524 A1 in view of McLaughlin: US 20090024416 A1 in further view of GREEN, US 20110258000 A1.

20. **As to claim 28**, claim 28 recites substantially the same limitations as claim 1, therefore, it is rejected under the same rationale. In addition, the combination of **Pollanz-McLaughlin** does not appear explicitly disclose de-identified healthcare data.

However, **Green** discloses de-identified healthcare data **(Green pa. [0060]) [process includes querying de-identified patient diagnosis/medical history data and determining the number of patients with specific diagnoses]**

Pollanz, McLaughlin and **GREEN** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Pollanz, McLaughlin** and **GREEN** before him or her to modify and configure the computing environment of **Pollanz-McLaughlin** to include parameters that would allow to store data in relational databases, that data query to produce de-identified data sets as taught by **GREEN.**

Thus, the motivation for doing so would have been to utilize the data captured in an integrated medical software system to conduct medical research, to maintain disease registries, to analyze the quality and safety of healthcare providers **(GREEN pa. [0002])**

21. **As to claim 29**, **Pollanz** teaches wherein the healthcare information provided absent authorization from the group of individuals is in conformity with the Health Insurance Portability and Accountability Act (HIPAA) (**Pollanz pa. [0003]) [executive laws that deal with the use of medical data in accordance with the provisions of the Patient's Bill of Rights Act, are summarized under the Health Insurance Portability and Accountability Act of 1996 (HIPAA)]**

Conclusion

22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2006/0184524	08-2006	Pollanz, Gunter	707/006
*	B	US-2005/0261941	11-2005	Scarlat, Alexander	705/003
*	C	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	D	US-2011/0258000	10-2011	GREEN et al.	705/3
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED
380	28-30,255-283	12/12/2013	ED
713	150-154,160-167,189-193	12/12/2013	ED
705	3, 5	12/12/2013	ED

SEARCH NOTES		
Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	12/12/2013	ED

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L5	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:28
L6	467	(produc$5 output) near5 (information data record) same (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:50
L7	1	5 and 6	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:51
L8	40	(produce producing produced output) near5 (information data record) same (patient individual) near5 un$1authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
L9	0	5 and 8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
L10	35	8 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:54
L11	0	L5 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
L12	985	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:57
L13	0	12 and (report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58
L14	5	(report) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 11:58

L15	188	((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:06
L16	10137562	(produc$5 display) ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
L17	2	(produc$5 display) near5 ((information data record)) same without near5 (patient individual) near5 authoriz$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:07
L18	167	15 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
L19	2	(((information data record)) same without near5 (patient individual) near5 authoriz$5).ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:08
L20	128	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
L21	0	L20 and un$1attainab$5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:46
L22	45317	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
L23	8	20 and 22	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:48
L24	8	23 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/12 12:49
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18

S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28

S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54

S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16

S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50

S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S58	556	(health near5 care) near5 (record data information) same (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:47
S59	36721	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S60	4	S58 and S59	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:48
S61	45185	713/168-174,182-186,202.ccls. 709/225,229.ccls. 726/2-8.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:50
S62	7	S58 and S61	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:51

S63	5	S62 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 10:52
S64	127	(de$5identif$5 un$1identif$5) near5 (((health near5 care) medical) near5 (data record history information))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:03
S65	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:05
S66	65	S64 and (group multi plurality several) near5 (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S67	61	S66 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:12
S68	0	S67 and (absent near5 authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:22
S69	33	S67 and (un$1authoriz$3)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:23
S70	4	S61 and S67	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2013/12/06 11:32

12/12/2013 2:55:00 PM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012	12/12/2013						
	1	✓	✓	✓						
	2	✓	✓	✓						
	3	✓	✓	✓						
	4	✓	✓	✓						
	5	✓	✓	✓						
	6	✓	✓	✓						
	7	✓	✓	✓						
	8	✓	✓	✓						
	9	✓	✓	✓						
	10	✓	✓	✓						
	11	✓	✓	✓						
	12	✓	✓	✓						
	13	✓	✓	✓						
	14	✓	✓	✓						
	15	✓	✓	✓						
	16	✓	✓	✓						
	17	✓	✓	✓						
	18	✓	✓	✓						
	19	✓	✓	✓						
	20	✓	✓	✓						
	21	✓	✓	✓						
	22	✓	✓	✓						
	23	✓	✓	✓						
	24	✓	✓	✓						
	25	✓	✓	✓						
	26	✓	✓	✓						
	27	✓	✓	✓						
	28			✓						
	29			✓						

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 05/07/2013
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
05/07/2013	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(2) *Paris Andrew*.

(3) *Jeffrey Barclay*.

(4) *Ashok Patel*.

Date of Interview: *02 May 2013*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☐112 ☐102 ☒103 ☒Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1*.

Identification of prior art discussed: *Schoenberg: US 20050234739 A1, McLaughlin: US 20090024416 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited arts. Claim 1 was discussed. Applicant provided the analysis of the claim. Applicant argued that Schoenberg does not disclose "providing the produced information to report the characteristics of the group absent authorization from the group of individuals"; Examiner explained to Applicant how the claimed limitation has been interpreted. Applicant agreed to amend the claim for more clarification and to move the prosecution. Applicant will submit an official amendment. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Examiner, Art Unit 2491	

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

PTO/SB/30 (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	12/827,745
Filing Date	June 30, 2010
First Named Inventor	Andrew L. Paris III
Art Unit	2491
Examiner Name	Evans Desrosiers
Attorney Docket Number	25412-0002001

This is a Request for Continued Examination (RCE) under 37 CFR 1 .114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

   a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

      i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

      ii. ☐ Other _____

   b. ☒ Enclosed

      i. ☒ Amendment/Reply

      ii. ☐ Affidavit(s)/ Declaration(s)

      iii. ☐ Information Disclosure Statement (IDS)

      iv. ☐ Other _____

2. Miscellaneous

   Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a

   a. ☐ period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

   b. ☐ Other _____

3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
   The Director is hereby authorized to charge the following fees any underpayment of fees or credit any overpayments to

   a. ☒ Deposit Account No. 06-1050 .

      i. ☒ RCE fee required under 37 CFR 1.17(e)

      ii ☒ Extension of time fee (37 CFR 1.136 and 1.17)

      iii ☒ Other any deficiencies

   b. ☐ Check in the amount of $ _____ enclosed

   c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature	/Jeffrey J. Barclay, Reg. No. 48,950/	Date	6 May 2013
Name (Print/Type)	Jeffrey J. Barclay	Registration No.	48,950

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature			
Name (Print/Type)		Date	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkFlow.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602

Title : DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL REPLY TO ACTION OF DECEMBER 5, 2012

AND REPLY TO ADVISORY ACTION OF FEBRUARY 22, 2013

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Currently Amended) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Currently Amended) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

28. (New) A computer-implemented method comprising:

receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information;

producing, by a processor, individual identifiers, wherein the identity of the individuals is unattainable from the individual identifiers, each individual identifier being

associated with a corresponding individual identifier in a set of de-identified healthcare data, and each individual identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual;

producing, absent authorization from the group of individuals, the requested healthcare information by identifying the individual identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced individual identifiers, wherein the produced healthcare information is absent personally identifiable information; and

providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals.

29. (New) The computer-implemented method of claim 28, wherein the healthcare information provided absent authorization from the group of individuals is in conformity with the Health Insurance Portability and Accountability Act (HIPAA).

REMARKS

The Applicant appreciates and would like to thank Examiners Evans Desrosiers and Ashok Patel for taking time out of their schedule to discuss the subject application on 2 May 2013 with the Applicant, Mr. Andrew L. Paris III, and the Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Along with discussing the current action, the pending claims and art references cited in the action were also discussed.

Claims 1-27 are pending in this application, with claims 1, 10 and 19 being independent and claims 28 and 29 being new. Favorable reconsideration is respectfully requested in view of the following amendments and comments of the Applicant, which are preceded by related comments of the Examiner in small bold type.

Claim Rejections – 35 USC § 103

Claims 1-7, 9-16, 18-25, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416.

Amended independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

Schoenberg is understood to describe a rule processing method that includes defining a target group of patients chosen from a group of existing patients, and taking an action concerning the target group of patients (please see abstract). The action concerning patients in the target group is taken by a medical provider, and the action may include "providing a medical report to a third party" (please see paragraph [0058]). In Schoenberg's system,

> "the target group of patients are chosen from existing group of patients of the medical service provider. As discussed above, these are the patients to which the medical service provider 18 has an access key that grants the medical service

provider with access to at least a portion of the patient's medical records" (please see paragraph [0055]).

To access the medical information Schoenberg's system requires the patient to provide an access key to the medical provider (please see paragraphs [0032]-[0035]). In fact, this authorization from the patient (i.e., the individual associated with the information) is so integral to Schoenberg's system that Schoenberg describes a patient's medical records being divided into levels with portions that are considered more confidential than other portions, and a case where the access key being generated by a patient will "allow the medical service provider to access *only* two portions of the patient's medical record" (please see paragraph [0037], emphasis added). Thus, Schoenberg does not disclose or suggest producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. Schoenberg appears to suggest the opposite.

Additionally, McLaughlin is not understood to remedy these deficiencies of Schoenberg.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Schoenberg and McLaughlin. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 8, 17, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416 in further view of Scarlat US 20050261941.

Scarlat is not understood to remedy the foregoing deficiencies of Schoenberg and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). However, the Applicant submits that similar to Schoenberg and McLaughlin, Scarlat does not disclose or suggest producing information that characterizes a group of

individuals from a set of private data representing characteristics of the individuals absent authorization from the group of individuals, and providing the produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Schoenberg, McLaughlin and Scarlat. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 8, 17 and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

New claim 28 has been added. Schoenberg, McLaughlin and Scarlat are not understood to disclose or suggest receiving a request for healthcare information that characterizes a group of individuals from healthcare data that comprises personally identifiable information; producing, by a processor, individual identifiers, wherein the identity of the individuals is unattainable from the individual identifiers, each individual identifier being associated with a corresponding individual identifier in a set of de-identified healthcare data, and each individual identifier in the set of de-identified healthcare data being associated with healthcare data for a corresponding individual; producing, absent authorization from the group of individuals, the requested healthcare information by identifying the individual identifiers in the set of de-identified healthcare data and the associated de-identified healthcare data that correspond to the produced individual identifiers, wherein the produced healthcare information is absent personally identifiable information; and providing the produced healthcare information to report the characteristics of the group absent authorization from the group of individuals. The new dependent claim 29 partakes of the novelty of parent independent claim 28 and, as such, has not been addressed specifically herein.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the

amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

The fees in the amount of $300 for the petition for extension of time and $250 for excess claims are being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account Authorization. Please apply any necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 6 May 2013

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

23025263.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR TWO-MONTH EXTENSION OF TIME UNDER 37 C.F.R. §1.136

Please extend the period for response to the action dated December 5, 2012, for two months to and including May 6, 2013 (May 5, 2013 being a Sunday).

The fees in the amount of $300 are being paid concurrently herewith. In addition, please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 6 May 2013

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

23025869.doc

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 2 months with $0 paid	2252	1	300	300

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
Request for Continued Examination	2801	1	600	600
		Total in USD ($)		**900**

Electronic Acknowledgement Receipt

EFS ID:	15697866
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	06-MAY-2013
Filing Date:	30-JUN-2010
Time Stamp:	14:11:10
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$900
RAM confirmation Number	428
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

1	Request for Continued Examination (RCE)	2001RCE.pdf	106599 a00eae6eabaf650913fd556fc77f73abd3984d32	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		2001Amendment.pdf	121576 d6c772b5eef37c83880f9559e73465b5886b0dd3	yes	10

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment Submitted/Entered with Filing of CPA/RCE	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	10

Warnings:					
Information:					
3	Extension of Time	2001EOT.pdf	39790 65803f107aeff60e73e39fcab16eecb9429f7c9c	no	1
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	32012 44f6783bce68b311ad674d11bd908d0b4e9b94f2	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	299977		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (07-06)
Approved for use through 1/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
12/827,745	06/30/2010	

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY ☒ RATE ($)	SMALL ENTITY ☒ FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =		OR	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =			X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 05/06/2013	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE ($)	SMALL ENTITY ADDITIONAL FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 29	Minus	** 27	= 2	X $40 =	80	OR	X $ =	
Independent (37 CFR 1.16(h))	* 4	Minus	***3	= 1	X $210 =	210	OR	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE	290	OR	TOTAL ADD'L FEE	

AMENDMENT	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)		RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =		OR	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =		OR	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

Legal Instrument Examiner:
/EVELYN NIMMONS/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 05/09/2013

ENIMMONS	SALE	#00000001	Mailroom Dt:	05/06/2013	061050	12827745	
		01	FC : 2201	210.00 DA			
		02	FC : 2202	80.00 DA			

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 02/22/2013
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
02/22/2013	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Response to Arguments

Argument 1

a. It is argued that Claims 1, 10, and 19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was no described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no "...absent authorization from the group of individuals..." supported by the specification; therefore, it is treated as new matter. Appropriate correction is required. As to the dependent claims 2-9, 11-18 and 20-27, these claims are at least rejected, directly or indirectly, on the rejected claims above. Therefore they are rejected based on the same rationale. (A*pplicant's remarks page 6)*

Examiner's response 1.a.

In response to applicant's argument, Examiner respectfully submits that the support for the limitation "absent authorization from the group of individuals" is being found in the originally filed specification at least at paragraph [0016]. Therefore, the rejection under 35 U.S.C. 112, first paragraph has been redrawn.

b. McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. McLaughlin appears to suggest the opposite. (A*pplicant's remarks page 7)*

Examiner's response 1.b.

In response to applicant's argument, Examiner respectfully submits that the examiner respectfully submits that the rejection of claim 1 did not indicate that McLaughlin discloses providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals. **Schoenberg** was used for that purpose. See "providing the produced information to report the characteristics of the group absent authorization from the group of individuals **(Schoenberg, Fig. 8 pa. [0057-0058]) [step (220, 222), define target group, process medical records and providing a medical report to a third party]**" Therefore, applicant's arguments are moot.

Argument 2

a. It is argued that Scarlat does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. (A*pplicant's remarks page 8)*

Examiner's response 2.a.

In response to applicant's argument, it is respectfully submitted that these arguments have been previously addressed in **Examiner's response 1.b.**

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Examiner, Art Unit 2491

Advisory Action Before the Filing of an Appeal Brief	**Application No.** 12/827,745	**Applicant(s)** PARIS, ANDREW L.
	Examiner EVANS DESROSIERS	**Art Unit** 2491

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 01 February 2013 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

NO NOTICE OF APPEAL FILED

1. ☒ The reply was filed after a final rejection. No Notice of Appeal has been filed. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance;

(2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114 if this is a utility or plant application. Note that RCEs are not permitted in design applications. The reply must be filed within one of the following time periods:

a) ☐ The period for reply expires _____months from the mailing date of the final rejection.

b) ☒ The period for reply expires on: (1) the mailing date of this Advisory Action; or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

c) ☐ A prior Advisory Action was mailed more than 3 months after the mailing date of the final rejection in response to a first after-final reply filed within 2 months of the mailing date of the final rejection. The current period for reply expires months from the mailing date of *the prior Advisory Action* or SIX MONTHS from the mailing date of the final rejection, whichever is earlier.

Examiner Note: If box 1 is checked, check either box (a), (b) or (c). ONLY CHECK BOX (b) WHEN THIS ADVISORY ACTION IS THE FIRST RESPONSE TO APPLICANT'S FIRST AFTER-FINAL REPLY WHICH WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. ONLY CHECK BOX (c) IN THE LIMITED SITUATION SET FORTH UNDER BOX (c). See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) or (c) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☐ The proposed amendments filed after a final rejection, but prior to the date of filing a brief, will not be entered because

a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);

b) ☐ They raise the issue of new matter (see NOTE below);

c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or

d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. ☐ Applicant's reply has overcome the following rejection(s): _____.

6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. ☒ For purposes of appeal, the proposed amendment(s): (a) ☐ will not be entered, or (b) ☒ will be entered, and an explanation of how the new or amended claims would be rejected is provided below or appended.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ The affidavit or other evidence filed after final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. ☐ The affidavit or other evidence filed after the date of filing the Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. ☐ The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

_____.

12. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____

13. ☐ Other: _____.

STATUS OF CLAIMS

14. The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: .

Claim(s) objected to: .

Claim(s) rejected: 1-27.

Claim(s) withdrawn from consideration: .

/EVANS DESROSIERS/
Examiner, Art Unit 2491

Datavant Exhibit 1002
Page 348 of 468

PLEASE ENTER

/Evans Desrosiers/

Attorney Docket No.: 25412-0002001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602

Title : DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF DECEMBER 5, 2012

Please amend the above-identified application as follows:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602

Title : DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO ACTION OF DECEMBER 5, 2012

Please amend the above-identified application as follows:

Listing of Claims:

1. (Previously presented) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Previously presented) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Previously presented) One or more computer readable storage devices storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

REMARKS

The Applicant appreciates and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application on 22 January 2013 with the Applicant, Mr. Andrew L. Paris III, and the Applicant's representatives, Jeffrey J. Barclay (Reg. No. 48,950) and Natalie K. Galley. Along with discussing the current action, the pending claims and art references cited in the action were also discussed. The Examiner agreed to withdraw the rejection under 35 U.S.C. 112.

Claims 1-27 are pending in this application, with claims 1, 10 and 19 being independent. Favorable reconsideration is respectfully requested in view of the following comments of the Applicant, which are preceded by related comments of the Examiner in small bold type:

Claim Rejections – 35 USC § 112

Claims 1, 10, and 19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was no described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no "…absent authorization from the group of individuals…" supported by the specification; therefore, it is treated as new matter. Appropriate correction is required.
As to the dependent claims 2-9, 11-18 and 20-27, these claims are at least rejected, directly or indirectly, on the rejected claims above. Therefore they are rejected based on the same rationale.

As agreed by the Examiner, support for the limitation "absent authorization from the group of individuals" can be found in the originally filed specification at least at paragraph [0016].

Claim Rejections – 35 USC § 103

Claims 1-7, 9-16, 18-25, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416.

Independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

McLaughlin is understood to describe a system for allowing access to patient information. Each patient has "one or more database records in which his or her medical information is stored…indexed by a unique alphanumeric identifier", where the "identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity" (please see paragraph [0044]). McLaughlin's system "scans the patient's finger image, reads and decrypts the corresponding finger image information…and if they match, permits encrypted data to thereafter be transferred between base unit 26 and database system 12" paragraph [0047]. To access the medical information McLaughlin's system requires the patient to provide biometric information, e.g., finger images, voice print, etc. (please also see paragraph [0024]) which is a form of authorizing access.

Although the information is stored in database records in such a way that it does not reveal the patient's identity, for the patient or another party to access the information the patient must authorize the access using his or her biometric data. In fact, this authorization from the patient (i.e., the individual associated with the information) is so integral to McLaughlin's system that McLaughlin describes a situation in which medical personnel would have to take a finger scan from an unconscious patient arriving by ambulance (please see paragraph [0052]). Thus, McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1. McLaughlin appears to suggest the opposite.

In addition, independent claim 1 is directed to a method that includes producing information that characterizes *a group* of individuals. McLaughlin does not teach such matter. By contrast, McLaughlin teaches producing information for a *single individual* only after authenticating his or her identity by comparing biometric information of the individual (please see paragraph [0024]). Although many patients' medical information may be stored in

McLaughlin's database 12, it is provided for only a single patient. Additionally, Schoenberg is not understood to remedy these deficiencies of McLaughlin.

For at least these reasons, independent claim 1 is believed to be patentable over any combination of Schoenberg and McLaughlin. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 8, 17, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416 in further view of Scarlat US 20050261941.

Scarlat is not understood to remedy the foregoing deficiencies of Schoenberg and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). However, the Applicant submits that similar to Schoenberg and McLaughlin, Scarlat does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by independent claim 1.

For at least these reasons, independent claim 1 is believed to be patentable over the combinations of Schoenberg, McLaughlin and Scarlat. Similarly, independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 8, 17 and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the

amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

Please apply any necessary charges or credits to Deposit Account 06-1050, referencing attorney docket number 25412-0002001. Respectfully submitted,

Date: 1 February 2013

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22950608.doc

Electronic Acknowledgement Receipt

EFS ID:	14851309
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	01-FEB-2013
Filing Date:	30-JUN-2010
Time Stamp:	11:47:24
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2001.pdf	123363 4881cca018549949c6cdb859c9cbef8daf34ca11	yes	9

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment After Final	1	1
	Claims	2	5
	Applicant Arguments/Remarks Made in an Amendment	6	9
Warnings:			
Information:			
	Total Files Size (in bytes):	123363	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (07-06)
Approved for use through 1/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
12/827,745	06/30/2010	

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY ☒ RATE ($)	SMALL ENTITY ☒ FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =		OR	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =			X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT 02/01/2013	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE ($)	SMALL ENTITY ADDITIONAL FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 27	Minus	** 27	= 0	X $31 =	0	OR	X $ =	
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $125 =	0	OR	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE	0	OR	TOTAL ADD'L FEE	

AMENDMENT	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)	OR	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =		OR	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =		OR	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))									
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
					TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

Legal Instrument Examiner:
/DEBORAH NASH/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 01/25/2013

FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	
NOTIFICATION DATE	DELIVERY MODE
01/25/2013	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(2) *Andrew L. Paris III*.

(3) *Jeffrey J, Barclay*.

(4) *Natalie Galley*.

Date of Interview: *22 January 2013*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☒ No.
If Yes, brief description: _____.

Issues Discussed ☐101 ☒112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1*.

Identification of prior art discussed: *Schoenberg: US 20050234739 A1, McLaughlin: US 20090024416 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art and potential amendments to overcome the prior arts cited. Claim 1 was discussed. Applicant provided the analysis of the claim. Applicant pointed out the suport for the claimed limitation "absent authorization from the group of individuals." Examiner agreed to redraw the 112 first paragraph rejections. Applicant will submit an official amendment. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Examiner, Art Unit 2491	

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 12/05/2012
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	

ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
12/05/2012	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *15 October 2012*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

5)☒ Claim(s) *1-27* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-27* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/30/10* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)

2) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

DETAILED ACTION

Claims 1-27 remain for examination. Claims 1, 10, and 19 have been amended. Applicant's arguments with respect to claims 1-27 have been considered but they are not persuasive. Accordingly, this action has been made FINAL.

Examiner's Note

Examiner has cited particular columns and line numbers in the references as applied to the claims for the convenience of the applicant. Although the specified citations are representative of the teachings of the art and are applied to the specific limitations within the individual claim, other passages and figures may apply as well. It is respectfully requested from the applicant in preparing responses, to fully consider the references in entirety as potentially teaching all or part of the claimed invention, as well as the context of the passage as taught by the prior art or disclosed by the Examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 10, and 19 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter

which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no **"…absent authorization from the group of individuals…**" supported by the specification; therefore, it is treated as new matter. Appropriate correction is required.

As to the dependent claims 2-9, 11-18 and 20-27, these claims are at least rejected, directly or indirectly, on the rejected claims above. Therefore they are rejected based on the same rationale.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-7, 9-16, 18-25, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 A1 in view of McLaughlin: US 20090024416 A1.

As to claim 1, **Schoenberg** teaches a computer-implemented method comprising: producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals

(Schoenberg, Fig. 8 pa. [0055-0056]) [define a target group of patients that are chosen from existing group of patients of the medical service provider… the target group of patients may be defined in various ways… (i.e., of those that have a specific medical conditions (e.g., high blood pressure or diabetes)]; and providing the produced information to report the characteristics of the group absent authorization from the group of individuals **(Schoenberg, Fig. 8 pa. [0057-0058]) [step (220, 222), define target group, process medical records and providing a medical report to a third party]**

It is noted that **Schoenberg** does not appear explicitly disclose wherein the identity of the individuals is unattainable from the produced information. However, **McLaughlin** discloses wherein the identity of the individuals is unattainable from the produced information **(McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]**

Schoenberg and **McLaughlin** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's

records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 2, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes producing a request token for each individual included in the group **(McLaughlin pa. [00287]) [a plurality of patient tokens, each token associable with an individual patient]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 3, the combination of **Schoenberg-McLaughlin** teaches in which producing the request token for each individual includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient…include biometric that to be uniquely identifiable with the patient… Information is stored in the memory of the token of an embodiment in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the

art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 4, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced **(McLaughlin pa. [0024]) [verifies the patient's identity by obtaining a biometric from the patient** *(note: the biometric is in token format)* **and comparing it to "corresponding information"** *(read token)* **stored in the token memory] [0222] [The matching server generates the identification number from the extracted finger minutiae template and compares the identification number to the stored number]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 5, the combination of **Schoenberg-McLaughlin** teaches in which the tokens associated with the information to be produced and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 6, the combination of **Schoenberg-McLaughlin** in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical

information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

As to claim 7, **Schoenberg** teaches in which producing information that characterizes the group includes requesting a predefined portion of the information **(Schoenberg, pa. [0013]) [processing a multi-portion medical record for each of a group…Each portion of the medical record is assigned a confidentiality level]**

As to claim 9, **Schoenberg** teaches in which the private data represents medical related information associated with the individuals of the group **(Schoenberg, Fig. 2 pa. [0029]) [medical records 66, 68, 70 are private data]**

As to claim 10-16, 18, claims 10-16 and 18 recite respectively substantial the same limitations as claims 1-7 and 9, but in the form of a system rather than a method, therefore, they are rejected under the same rationale.

As to claim 19-25, 27, claims 19-25 and 27 recite respectively substantial the same limitations as claims 1-7 and 9, but in the form of a computer readable media rather than a method, therefore, they are rejected under the same rationale.

Claims 8, 17, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 A1 in view of McLaughlin: US

20090024416 A1 in further view of Scarlat US 20050261941 A1

As to claims 8, 17, 26, the combination of **Schoenberg-McLaughlin** does not appear explicitly disclose in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

However, **Scarlat** discloses in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals **(Scarlat, Fig. 3 pa. [0057]) [the results provided in the second query result, query result (2), also include, the number of patients in the sub-group]**

Schoenberg, McLaughlin and **Scarlat** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg, McLaughlin** and **Scarlat** before him or her to modify and configure the computing environment of **Schoenberg-McLaughlin** to include parameters that would allow to analyze statistically of existing medical/healthcare databases to provide a patient and/or caregiver with an objective basis for making decisions between different treatments as taught by **Scarlat.** Thus, the motivation for doing so would have been to providing an evidenced based medical decision support system and associated method that utilizes existing database systems to automatically derive information through ad hoc query and statistical analysis whereby the derived information is fed back to a user in near real time **(Scarlat pa. [0006])**

Response to Arguments

Argument 1

a. It is argued that McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by amended independent claim 1. McLaughlin appears to suggest the opposite. Additionally, Schoenberg is not understood to remedy these deficiencies of McLaughlin (*applicant's remarks page 8)*

Examiner's response 1.a.

In response to applicant's argument, Examiner respectfully submits that claimed limitation is to be given their broadest reasonable interpretation during prosecution, and the scope of a claim cannot be narrowed by reading disclosed limitations into the claim. See In re Morris, 127 F.3d 1048, 1054, 44 USPQ2D 1023, 1027 (Fed. Cir. 1997); In re Zletz, 893 F.2d 319, 321, 13 USPQ2D 1320, 1322 (Fed. Cir. 1989); In re Prater, 415 F.2d 1393, 1404, 162 USPQ 541,550 (CCPA 1969). Thus, McLaughlin fairly discloses providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals (McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]

b. The Applicant submits that similar to Schoenberg and McLaughlin, Scarlat does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by amended independent claim 1 (*applicant's remarks page 8)*

Examiner's response 1.b.

In response to applicant's argument, Examiner respectfully submits that that these arguments have been previously addressed in **Examiner's response 1.a.**

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to

5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Examiner, Art Unit 2491

/Ashok B. Patel/
Supervisory Patent Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2005/0234739	10-2005	Schoenberg, Roy	705/002
*	B	US-2009/0024416	01-2009	McLaughlin et al.	705/3
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	32677	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/11/20 13:48
L2	0	L1 and (absent near5 authoriz$5 near5 group with (individual people person patient user))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/11/20 13:49
L3	0	L1 and (absent near5 authoriz$5 near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/11/20 13:49
L4	1	(absent near5 authoriz$5 near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/11/20 13:50
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26

S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18
S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2012/05/31 16:27

			IBM_TDB			
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:55
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping	US-PGPUB;	OR	OFF	2012/05/31

		grouped) with (patient individual) same (medical near5 record)	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59

S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07
S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07

11/20/2012 2:46:54 PM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012	11/20/2012							
	1	✓	✓							
	2	✓	✓							
	3	✓	✓							
	4	✓	✓							
	5	✓	✓							
	6	✓	✓							
	7	✓	✓							
	8	✓	✓							
	9	✓	✓							
	10	✓	✓							
	11	✓	✓							
	12	✓	✓							
	13	✓	✓							
	14	✓	✓							
	15	✓	✓							
	16	✓	✓							
	17	✓	✓							
	18	✓	✓							
	19	✓	✓							
	20	✓	✓							
	21	✓	✓							
	22	✓	✓							
	23	✓	✓							
	24	✓	✓							
	25	✓	✓							
	26	✓	✓							
	27	✓	✓							

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

SEARCHED

Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED
380	28-30,255-283	11/20/2012	ED
713	150-154,160-167,189-193	11/20/2012	ED
705	3, 5	11/20/2012	ED

SEARCH NOTES

Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	11/20/2012	ED

INTERFERENCE SEARCH

Class	Subclass	Date	Examiner

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT IN REPLY TO ACTION OF JUNE 14, 2012

Please amend the above-identified application as follows:

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A computer-implemented method comprising:

producing, by a processor, information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

2. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. (Original) The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. (Original) The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. (Original) The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. (Original) The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. (Original) The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. (Original) The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. (Currently Amended) A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group absent authorization from the group of individuals.

11. (Original) The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. (Original) The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. (Original) The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. (Original) The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. (Original) The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. (Original) The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. (Original) The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. (Original) The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. (Currently Amended) One or more computer readable storage devices ~~media~~ storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

20. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. (Original) The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. (Original) The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. (Original) The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. (Original) The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. (Original) The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. (Original) The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

REMARKS

The Applicant appreciates and would like to thank Examiner Evans Desrosiers for taking time out of his schedule to discuss the subject application on 4 September 2012 with the Applicant, Mr. Andrew L. Paris III, and the Applicant's representative, Mr. Jeffrey J. Barclay (Reg. No. 48,950). Along with discussing the current action, the pending claims and art references cited in the action were also discussed. The content of this response reflects this discussion with the Examiner.

Claims 1-27 are pending in this application, with claims 1, 10 and 19 being independent. Independent claims 1, 10 and 19 have been amended. No new matter has been added by way of these amendments. Favorable reconsideration and further examination of the action is respectfully requested in view of the foregoing amendments and following comments of the Applicant, which are preceded by related comments of the Examiner in small bold type:

Claim Rejections – 35 USC § 101

Claims 1-9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Not conceding to the Examiner's position, independent claim 1 has been amended as discussed with the Examiner to expedite prosecution. Claims 2-9 directly or indirectly depend upon amended independent claims 1. As such, Applicant submits that claims 1-9 are in proper form regarding 35 USC § 101.

Claims 19-27 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Not conceding to the Examiner's position, independent claim 19 has been amended as discussed with the Examiner to expedite prosecution. Claims 20-27 directly or indirectly depend upon amended independent claim 19. As such, Applicant submits that claims 19-27 are in proper form regarding 35 USC § 101.

Claim Rejections – 35 USC § 103

Claims 1-7, 9-16, 18-25, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416.

Amended independent claim 1 is directed to a computer-implemented method that includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group absent authorization from the group of individuals.

In the current action the Examiner appears to concede that Schoenberg does not teach each feature of independent claim 1. In particular, on page 5 of the current action the Examiner states "It is noted that Schoenberg does not appear [to] explicitly disclose wherein the identity of the individuals is unattainable from the produced information". To allegedly provide this subject matter, the Examiner points to the McLaughlin reference. In particular, the Examiner points to paragraphs [0023] and [0287], which read:

> [0023] Patient healthcare information, such as medical diagnoses, treatments, caregiver comments and impressions, medications, test results, diagnostic data and the like, are primarily stored in a secure database system that can be referred to as an electronic vault and is located remotely from the healthcare professional's clinic, office, hospital or other site. Each patient is issued an electronic token, which can be card-like, pendant-like or have any other suitably portable shape or structure. The patient's name and other such biographical information are stored in the memory of the token itself. An identifier is also stored in the token memory and is used as an index to the corresponding patient records stored in the database system. To ensure privacy, no biographical information or other personal information revealing the patient's identity is stored in the database system. The patient's insurance information may also be stored in the token memory. Vital medical information, such as the patient's blood type, current medications, allergies to medicines, emergency contacts, and other information that could be needed by emergency medical personnel, may also be stored in the token memory. Information stored in token memory is encrypted to safeguard against unauthorized access and tampering.

> [0287] The systems and methods described herein include a system for managing individual healthcare information. The system of an embodiment includes a database system for healthcare information relating to a plurality of patients. The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information. The system of an embodiment includes an interface to a wide-area computer network. The system of an embodiment includes a plurality of patient tokens, each token associable with an individual patient and portable by the individual patient and having memory in

which are storable biographical information identifying the individual patient and an identifier code corresponding to the identifier code in the database system relating to a corresponding entry for the individual patient in the database system. The system of an embodiment includes a plurality of base units remotely located from the database system, each base unit associable with a healthcare provider. The base unit of an embodiment includes a wide-area network interface through which information can be communicated with the database system. The base unit of an embodiment includes a token interface circuit with which any one of the tokens can communicate when placed in proximity with a portion of the token interface circuit. The base unit of an embodiment includes a biometric processor with a sensor. The base unit of an embodiment is configured to support biographical information identifying a patient to be read from the memory of a token only if the biometric processor verifies the patient's identity by determining the patient has a biometric predetermined to be uniquely identifiable with the patient and not identifiable with any other patients. The base unit of an embodiment is configured to support healthcare information entries for the patient to be read from the database system via a wide-area network only if the biometric processor verifies the patient's identity by determining the patient has a biometric predetermined to be uniquely identifiable with the patient and not identifiable with any other patients.

McLaughlin is understood to describe a two-part system for allowing access to patient information. Along with the patient providing an electronic device for accessing information, biometric information (e.g., finger images, voice print, etc.) is also provided by the patient for authorizing access (please also see paragraphs [0022] and [0024]). As such, prior to access, authorization is needed from the individual associated with the information. Thus, McLaughlin does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by amended independent claim 1. McLaughlin appears to suggest the opposite. Additionally, Schoenberg is not understood to remedy these deficiencies of McLaughlin.

For at least these reasons, amended independent claim 1 is believed to be patentable over any combination of Schoenberg and McLaughlin. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 2-7, 9, 11-16, 18, 20-25 and 27 respectively partake of the novelty of their parent independent claims and, as such, have not been addressed specifically herein.

Claims 8, 17, and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 in view of McLaughlin: US 20090024416 in further view of Scarlat: US 20050261941.

Scarlat is not understood to remedy the foregoing deficiencies of Schoenberg and McLaughlin. Rather, Scarlat appears to describe an evidence-based medical decision support system to assist a caregiver or patient in deciding between different diagnostic and/or therapeutic modalities based on statistically sound, relevant and unbiased evidence (please see paragraphs [0006] and [0007]). However, the Applicant submits that similar to Schoenberg and McLaughlin, Scarlat does not disclose or suggest providing produced information to report characteristics of a group of individuals absent authorization from the group of individuals, as required by amended independent claim 1.

For at least these reasons, amended independent claim 1 is believed to be patentable over the combinations of Schoenberg, McLaughlin and Scarlat. Similarly, amended independent claims 10 and 19 are also believed to be allowable for at least the same reasons noted above. The dependent claims 8, 17 and 26 respectively partake of the novelty of their parent independent claim and, as such, have not been addressed specifically herein.

It is believed that all of the pending claims have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this paper should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this paper, and the amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

In view of the foregoing remarks, the entire application is now believed to be in condition for allowance, and such action is respectfully requested at the Examiner's earliest convenience. Applicants' attorney can be reached at the address shown below. Telephone calls regarding this application should be directed to 617-368-2191.

The fee of $75 for the petition for extension of time is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account Authorization. Please apply any other charges or credits to deposit account 06-1050, referencing Attorney Docket No. 25412-0002001.

Respectfully submitted,

Date: 15 October 2012

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22862748.doc

Electronic Patent Application Fee Transmittal

Application Number:	12827745
Filing Date:	30-Jun-2010
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 1 month with $0 paid	2251	1	75	75

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Miscellaneous:				
			Total in USD ($)	**75**

Electronic Acknowledgement Receipt

EFS ID:	13986898
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	15-OCT-2012
Filing Date:	30-JUN-2010
Time Stamp:	16:09:47
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$75
RAM confirmation Number	3128
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Exhibit 1002

1	Extension of Time	2001Ext.pdf	39788 2a9f5ec023bb82a03f84790626ca148811c0c1c4	no	1
Warnings:					
Information:					
2		2001Resp.pdf	116399 fc370b219f19106201899a6d852a2161d2d69a88	yes	10

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	5
	Applicant Arguments/Remarks Made in an Amendment	6	10

Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	29878 fee6524a10e7ffcc8558eae9f1baec29379a29a2	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	186065		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: 2491
Serial No.	: 12/827,745	Examiner	: Evans Desrosiers
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR ONE-MONTH EXTENSION OF TIME UNDER 37 C.F.R. §1.136

Please extend the period for response to the action dated June 14, 2012, for one month to and including October 15, 2012 (October 14, 2012 being a Sunday).

The fees in the amount of $75 are being paid concurrently herewith. In addition, please apply any other necessary charges or credits to Deposit Account 06-1050, referencing the above attorney docket number.

Respectfully submitted,

Date: 15 October 2012

/Jeffrey J. Barclay, Reg. No. 48,950/
Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22925955.doc

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 09/13/2012
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
09/13/2012	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Applicant-Initiated Interview Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

All participants (applicant, applicant's representative, PTO personnel):

(1) *EVANS DESROSIERS*.

(3) *Jeffrey J. Barclay*.

(2) *Andrew Paris*.

(4)_____.

Date of Interview: *04 September 2012*.

Type: ☒ Telephonic ☐ Video Conference
☐ Personal [copy given to: ☒ applicant ☒ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☐ No.
If Yes, brief description: _____.

Issues Discussed ☒101 ☐112 ☐102 ☒103 ☐Others
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: *1 and 9*.

Identification of prior art discussed: *Schoenberg: US 20050234739 A1, McLaughlin: US 20090024416 A1.*.

Substance of Interview
(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Applicant initiated the interview to discuss cited art and potential amendments to overcome the prior arts cited. Claim 1 and 9 were discussed. Applicant provided the analysis of the claim. Applicant agreed to amend claims 1 , 9 and 19-27 to overcome the 101 rejections. Furthermore, Applicant suggested potential amendments to the claims 1 and 9 to overcome Schoenberg and McLaughlin. Applicant will submit an official amendment. Examiner will conduct a further search and/or consideration in ligth of the amendment when received.

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

/EVANS DESROSIERS/ Examiner, Art Unit 2491	/Ashok B. Patel/ Supervisory Patent Examiner, Art Unit 2491

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/827,745	06/30/2010	Andrew L. Paris III	25412-0002001	5602

26161 7590 06/14/2012
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER	
DESROSIERS, EVANS	
ART UNIT	PAPER NUMBER
2491	

NOTIFICATION DATE	DELIVERY MODE
06/14/2012	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No.	Applicant(s)	
	12/827,745	PARIS, ANDREW L.	
	Examiner	Art Unit	
	EVANS DESROSIERS	2491	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *1* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *30 June 2010*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

5)☒ Claim(s) *1-27* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *1-27* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *06/30/2010* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

12)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

Detailed Action

1. This communication is in response to the application filed on 06/30/2010. In which Claims 1-27 are presented for examination.

Oath/Declaration

2. The applicant's oath/declaration filed on 06/30/2010 has been reviewed by the examiner and is found to conform to the requirements prescribed in **37 C.F.R. 1.63.**

Drawings

3. The applicant's drawings submitted on 06/30/2010 are acceptable for examination purposes.

Priority

4. The examiner believes claims 1-27 are supported by applicant's provisional US patent application serial No. 61/222,428 and thus these claims merit the earliest priority date of the US patent, 07/01/2009.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

> Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

5. Claims 1-9 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

6. As to independent claim 1, while the claim recites a series of steps or acts to be performed, a statutory "process" under 35 U.S.C. § 101 must (1) be tied to a particular machine, or (2) transform underlying subject matter (such as an article or material) to a different state or thing. *See page 10 of In Re Bilski 88 USPQ2d 1385*. Specifically, claim 1 recites “A computer-implemented method comprising: producing information that characterizes a group … providing the produced information …”, but nowhere in the claim does it state what particular apparatus does (or is positively tied with) these series of steps. Because the instant claim is neither positively tied to a particular machine that accomplishes the claimed method steps nor transforms underlying subject matter of the claim to a different state or thing, the claim therefore does not qualify as a statutory process under 35 U.S.C. § 101.

As to dependent claims 2-9, they are rejected under 35 U.S.C. § 101 for depending upon the non-statutory subject matter recited by independent claim 1.

7. Claims 19-27 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

8. Claims 19-27 recite a “computer readable media…” However, the usage of the phrase “computer readable media” is broad enough to include both “non-transitory" and “transitory” (moving electrons, etc) media. The specification does not clearly limit the utilization of a non-transitory computer readable media and, thus does not constitute functional descriptive material. Therefore, when the broadest reasonable interpretation of a claim covers a signal *per se*, the claim must be rejected under 35 U.S.C. § 101 as

covering non-statutory subject matter. *See In re Nuijten, 500 F. 3d 1346, 1356-57 (Fed. Cir. 2007)* (transitory embodiments are not directed to statutory subject matter).

The Examiner suggests that the Applicant replace the term "computer-readable media" with the term "non-transitory computer-readable media" to the media as recited in the claim(s) in order to properly render the claim(s) in statutory form in view of their broadest reasonable interpretation in light of the originally filed specification. Applicant is suggested to review page 4 of the and *Interim Examination Instructions for Evaluating Subject Matter Eligibility Under 35 U.S.C. § 101*, Aug. 24, 2009, under section II. Subsection (c), which describes a "non-transitory computer readable media" being patent-eligible subject matter.

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

10. Claims 1-7, 9-16, 18-25, and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schoenberg: US 20050234739 A1 in view of McLaughlin: US 20090024416 A1.

11. **As to claim 1**, **Schoenberg** teaches a computer-implemented method comprising: producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals **(Schoenberg, Fig. 8 pa.**

[0055-0056]) [define a target group of patients that are chosen from existing group of patients of the medical service provider… the target group of patients may be defined in various ways… (i.e., of those that have a specific medical conditions (e.g., high blood pressure or diabetes)]; and providing the produced information to report the characteristics of the group **(Schoenberg, Fig. 8 pa. [0057-0058]) [step (220, 222), define target group, process medical records and providing a medical report to a third party]**

It is noted that **Schoenberg** does not appear explicitly disclose wherein the identity of the individuals is unattainable from the produced information.

However, **McLaughlin** discloses wherein the identity of the individuals is unattainable from the produced information **(McLaughlin, pa. [0287]) [The database entries of the healthcare information for each patient are identified only by an identifier code and not identified by name or other biographical information, also, see pa. [0044] "the identifier can be randomly generated or generated using a hash algorithm such that it does not reveal the patient's identity"]**

Schoenberg and **McLaughlin** are analogous art because they are from the same field of endeavor; especially they are from the field of securing patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so

would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

12. **As to claim 2**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes producing a request token for each individual included in the group **(McLaughlin pa. [00287]) [a plurality of patient tokens, each token associable with an individual patient]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

13. **As to claim 3**, the combination of **Schoenberg-McLaughlin** teaches in which producing the request token for each individual includes encrypting respective data that identifies each individual **(McLaughlin pa. [00287-0288]) [healthcare information entries for the patient…include biometric that to be uniquely identifiable with the patient… Information is stored in the memory of the token of an embodiment in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin**

before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

14. **As to claim 4**, the combination of **Schoenberg-McLaughlin** teaches in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced **(McLaughlin pa. [0024]) [verifies the patient's identity by obtaining a biometric from the patient** *(note: the biometric is in token format)* **and comparing it to "corresponding information"** *(read token)* **stored in the token memory] [0222] [The matching server generates the identification number from the extracted finger minutiae template and compares the identification number to the stored number]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

15. **As to claim 5**, the combination of **Schoenberg-McLaughlin** teaches in which the tokens associated with the information to be produced and the request tokens are similarly encrypted **(McLaughlin pa. [00288]) [tokens in encrypted format]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

16. **As to claim 6**, the combination of **Schoenberg-McLaughlin** in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches **(McLaughlin pa. [0222-0223]) [matching server compares the identification number to the stored number and generates a token in response to the match]** Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg** and **McLaughlin** before him or her to modify and configure the computing environment of **Schoenberg** to an electronic healthcare record storage and retrieval in which security of the patient's records to be controlled as taught by **McLaughlin.** Thus, the motivation for doing so would have been to ensure privacy, and that no biographical

information or other personal information revealing the patient's identity **(McLaughlin pa. [0023])**

17. **As to claim 7**, **Schoenberg** teaches in which producing information that characterizes the group includes requesting a predefined portion of the information **(Schoenberg, pa. [0013]) [processing a multi-portion medical record for each of a group…Each portion of the medical record is assigned a confidentiality level]**

18. **As to claim 9**, **Schoenberg** teaches in which the private data represents medical related information associated with the individuals of the group **(Schoenberg, Fig. 2 pa. [0029]) [medical records 66, 68, 70 are private data]**

19. **As to claim 10-16, 18**, claims 10-16 and 18 recite respectively substantial the same limitations as claims 1-7 and 9, but in the form of a system rather than a method, therefore, they are rejected under the same rationale.

20. **As to claim 19-25, 27**, claims 19-25 and 27 recite respectively substantial the same limitations as claims 1-7 and 9, but in the form of a computer readable media rather than a method, therefore, they are rejected under the same rationale.

21. Claims 8, 17, and 26 are rejected under 35 U.S.C. 103(a) as being

unpatentable over Schoenberg: US 20050234739 A1 in view of McLaughlin: US 20090024416 A1 in further view of Scarlat US 20050261941 A1

22. **As to claims 8, 17, 26**, the combination of **Schoenberg-McLaughlin** does not appear explicitly disclose in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

However, **Scarlat** discloses in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals **(Scarlat, Fig. 3 pa. [0057]) [the results provided in the second query result, query result (2), also include, the number of patients in the sub-group]**

Schoenberg, McLaughlin and **Scarlat** are analogous art because they are from the same field of endeavor; especially they are from the field of management of patients' medical records. Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention, having the teachings of **Schoenberg, McLaughlin** and **Scarlat** before him or her to modify and configure the computing environment of **Schoenberg-McLaughlin** to include parameters that would allow to analyze statistically of existing medical/healthcare databases to provide a patient and/or caregiver with an objective basis for making decisions between different treatments as taught by **Scarlat.** Thus, the motivation for doing so would have been to providing an evidenced based medical decision support system and associated method that utilizes existing database systems to automatically derive information through ad hoc query and statistical analysis whereby the derived information is fed back to a user in near real time.

(Scarlat pa. [0006])

Conclusion

23. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EVANS DESROSIERS whose telephone number is (571)270-5438. The examiner can normally be reached on Monday-Friday 9:00 am to 5:30 pm, EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ashokkumar Patel can be reached on (571) 272-3972. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/EVANS DESROSIERS/
Examiner, Art Unit 2491

Notice of References Cited	Application/Control No. 12/827,745	Applicant(s)/Patent Under Reexamination PARIS, ANDREW L.	
	Examiner EVANS DESROSIERS	Art Unit 2491	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2005/0234739	10-2005	Schoenberg, Roy	705/002
*	B	US-2009/0024416	01-2009	McLaughlin et al.	705/3
*	C	US-2005/0261941	11-2005	Scarlat, Alexander	705/003
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	3	"11567577"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:15
S2	744	(healthcare medica) with (data information) with history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:18
S3	208	S2 and ((data information) with group with (individual patient person people))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:20
S4	19	S3 and (encrypt$ with (individual patient person people) with (identity ID identification identifier))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:22
S5	30884	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S6	0	S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S7	0	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:25
S8	2	S2 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:26
S9	1099	(healthcare medica) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:30
S10	10	S5 and S9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:31
S11	8319	(healthcare medical) same (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 15:58
S12	278	S11 and (encrypt$5) near5 (individual patient) near5 (information data)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:18

S13	32	S11 and (encrypt$5) near5 (individual patient) near5 (identity identification ID)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:20
S14	62	S11 and (token key) with (group several plurality) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:28
S15	55	S14 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 16:29
S16	2	(10/825352).APP.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:21
S17	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:56
S18	60	S17 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:57
S19	2	S18 and (compar$5 match$5) near5 (token key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/30 17:58
S20	69	group$5 near5 (patient individual) with (medical) with (data information) near5 history	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S21	60	S20 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:24
S22	38	S21 and (number with (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:25
S23	8	S21 and (number near5 (patient individual) with (group set))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:27
S24	5838	(medical record) with (categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:52
S25	180	S24 and (compar$5 or match$5) near5 (token or key)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:53
S26	3325	S25 (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 16:54
S27	6	S25 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	OFF	2012/05/31 16:55

			IBM_TDB			
S28	222	S24 and (number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S29	346	S24 and (number near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:04
S30	6	S24 and ((minimum maximum) near5 number near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:05
S31	352	S24 and ((number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:07
S32	119	S31 and ("705".clas.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S33	112	S32 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:10
S34	5528	S24 and ((determin$5 comput$5) (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S35	28	S24 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) with group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S36	26	S35 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:12
S37	180811	(categoriz$5 group grouping grouped) with (patient individual)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S38	379	(categoriz$5 group grouping grouped) with (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:16
S39	236	(categoriz$5 group grouping grouped) near5 (patient individual) same (medical near5 record)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S40	0	S39 and ((determin$5 comput$5) near5 (number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S41	30	S39 and ((number quantity) near5 (patient individual) near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:17
S42	28	S41 and (@pd or @ptad or	US-PGPUB;	OR	OFF	2012/05/31

		@prad or @ad or @rlad)<"20090701"	USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB			17:17
S43	109322	"705".clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:41
S44	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S45	31843	S43 and (minimum number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S46	31843	S43 and (minimum nera5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:42
S47	2	S43 and (minimum near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S48	97352	S43 and (determin$5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S49	6	S43 and (determin$5 near5 number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:43
S50	144	S43 and (number near5 patient near5 group)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:50
S51	138	S50 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:51
S52	30901	380/28-30,255-283.ccls. 713/150-154,160-167,189-193.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S53	0	S42 and S52	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 17:59
S54	3	(("7304852") or ("6041347") or ("20040205540")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:03
S55	207	(medical near5 record) same (group near5 (patient individual))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:06
S56	36	S55 and (number quantity) near5 (patient individual) with group	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07

S57	33	S56 and (@pd or @ptad or @prad or @ad or @rlad)<"20090701"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; IBM_TDB	OR	OFF	2012/05/31 18:07

6/1/2012 10:20:29 AM
C:\Users\edesrosiers\Documents\EAST\Workspaces\12827745.wsp

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	**Art Unit**
	EVANS DESROSIERS	2491

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	06/01/2012								
	1	✓								
	2	✓								
	3	✓								
	4	✓								
	5	✓								
	6	✓								
	7	✓								
	8	✓								
	9	✓								
	10	✓								
	11	✓								
	12	✓								
	13	✓								
	14	✓								
	15	✓								
	16	✓								
	17	✓								
	18	✓								
	19	✓								
	20	✓								
	21	✓								
	22	✓								
	23	✓								
	24	✓								
	25	✓								
	26	✓								
	27	✓								

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	12827745	PARIS, ANDREW L.
	Examiner	Art Unit
	EVANS DESROSIERS	2491

SEARCHED

Class	Subclass	Date	Examiner
380	28-30,255-283	6/1/2012	ED
713	150-154,160-167,189-193	6/1/2012	ED
705	3, 5	6/1/2012	ED

SEARCH NOTES

Search Notes	Date	Examiner
INVENTORS	6/1/2012	ED
ASSIGNEE	6/1/2012	ED
EAST:US-PGPUB;USPAT; USOCR;FPRS; EPO; JPO;IBM_TDB	6/1/2012	ED

INTERFERENCE SEARCH

Class	Subclass	Date	Examiner

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 5602

SERIAL NUMBER	FILING or 371(c) DATE RULE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
12/827,745	06/30/2010	713	2491	25412-0002001

APPLICANTS
Andrew L. Paris III, Victor, NY;

**** CONTINUING DATA ***************************
This appln claims benefit of 61/222,428 07/01/2009

**** FOREIGN APPLICATIONS ***************************

**** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **** ** SMALL ENTITY **
07/09/2010

Foreign Priority claimed ☐ Yes ☑ No 35 USC 119(a-d) conditions met ☐ Yes ☑ No Verified and Acknowledged /EVANS DESROSIERS/ Examiner's Signature	☐ Met after Allowance Initials	STATE OR COUNTRY	SHEETS DRAWINGS	TOTAL CLAIMS	INDEPENDENT CLAIMS
		NY	7	27	3

ADDRESS
FISH & RICHARDSON P.C. (BO)
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022
UNITED STATES

TITLE
De-identifying Medical History Information for Medical Underwriting

FILING FEE RECEIVED		
644	FEES: Authority has been given in Paper No._____ to charge/credit DEPOSIT ACCOUNT No._____ for following:	☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Andrew L. Paris III	Art Unit	: Unknown
Serial No.	: 12/827,745	Examiner	: Unknown
Filed	: June 30, 2010	Conf. No.	: 5602
Title	: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATUS INQUIRY

Applicant respectfully inquires as to the status of the above application. The application was filed on June 30, 2010 and its last known status was: Application Dispatched from Preexam, Not Yet Docketed.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 13 June 2011

Jeffrey J. Barclay
Reg. No. 48,950

Customer Number 26161
Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22651233.doc

Electronic Acknowledgement Receipt

EFS ID:	10290170
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Paul Micele
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	13-JUN-2011
Filing Date:	30-JUN-2010
Time Stamp:	15:40:29
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	25412.pdf	25495 dc9320c26e11b140f1d5aa38cea06e6c9a446567	no	1

Warnings:	
Information:	

Total Files Size (in bytes):	25495

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
12/827,745	06/30/2010	2856	644	25412-0002001	27	3

CONFIRMATION NO. 5602

26161
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

FILING RECEIPT



Date Mailed: 07/14/2010

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Applicant(s)

Andrew L. Paris III, Victor, NY;

Assignment For Published Patent Application

Vigilytics

Power of Attorney: The patent practitioners associated with Customer Number 26161

Domestic Priority data as claimed by applicant

This appln claims benefit of 61/222,428 07/01/2009

Foreign Applications

If Required, Foreign Filing License Granted: 07/09/2010

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/827,745**

Projected Publication Date: Request for Non-Publication Acknowledged

Non-Publication Request: Yes

Early Publication Request: No
** **SMALL ENTITY** **

Title

De-identifying Medical History Information for Medical Underwriting

Preliminary Class

073

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FISH & RICHARDSON P.C.

Street Address
225 FRANKLIN STREET
BOSTON, MASSACHUSETTS
02110-2804

Mail Address
P.O. BOX 1022
MINNEAPOLIS, MINNESOTA
55440-1022

Telephone
617 542-5070

Facsimile
877 769-7945

WEB SITE
WWW.FR.COM

Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

June 30, 2010

Attorney Docket No.: 25412-0002001

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Presented for filing is a new patent application claiming priority from a provisional patent application of:

Applicant: ANDREW L. PARIS III

Title: DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING

Assignee: Vigilytics

Enclosed are the following papers, including those required to receive a filing date under 37 C.F.R. § 1.53(b):

	Pages
Specification	15
Claims	3
Abstract	1
Declaration	2
Drawing(s)	7

Enclosures:

— Nonpublication Request Under 35 U.S.C. 122(b)(2)(B)(i), 1 page.

This application claims priority under 35 USC §119(e) to U.S. Patent Application Serial No. 61/222,428, filed on July 1, 2009.

Applicant claims small entity status. See 37 CFR 1.27.

ATLANTA
BOSTON
DALLAS
DELAWARE
HOUSTON
MUNICH
NEW YORK
SILICON VALLEY
SOUTHERN CALIFORNIA
TWIN CITIES
WASHINGTON, DC

Basic Filing Fee			$82
Search Fee			$270
Examination Fee			$110
Total Claims 27	over 20	**7 x $26**	$182
Independent Claims 3	over 3	**0 x $110**	$0
Fee for Multiple Dependent claims			$0
Fee for each additional 50 pages of Specification and Drawings over 100			$0
26(total pages)*.75 = 20 - 100/50 = 0 x			
Total Filing fee			$644

The filing fee in the amount of $644 is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization. Please apply all charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 25412-0002001.

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at (617) 542-5070.

Please direct all correspondence to the following:

26161
PTO Customer Number

Respectfully submitted,

Jeffrey J. Barclay
Reg. No. 48,950
Enclosures
JFB/pxm
22449025.doc

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)		
	First Named Inventor	Andrew L. Paris III
	Title	De-identifying Medical History Information for Medical Underwriting
	Attorney Docket Number	25412-0002001

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

[signature]	30 June 2016
Signature	Date
Jeffrey J. Barclay	48,950
Typed or printed name	Registration Number, if applicable
617-542-5070	
Telephone Number	

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

De-identifying Medical History Information for Medical Underwriting

CLAIM OF PRIORITY

[001] This application claims priority under 35 USC §119(e) to U.S. Patent Application Serial No. 61/222,428, filed on July 1, 2009, the entire contents of which are hereby incorporated by reference.

BACKGROUND

[002] The present disclosure relates to processing and transmitting personal data, the dissemination of which is restricted by federal law.

[003] Due to federal privacy laws, companies that offer health insurance to small and midsize groups (containing 10 – 1000 individuals) are often unable to obtain the health history data they need to estimate the risk of insuring such groups commonly referred to as "experience rating". This frequently leads to less than optimal pricing for the companies, the groups, or both. Healthcare providers such as pharmacies and hospitals generate private healthcare data about patients, including medical and prescription drug history, and administrative healthcare claims data. Data that associates patient identity with health information is known as protected health information (PHI). Healthcare providers can store protected health information in electronic databases for future use in patient care and insurance claims processing. Insurance companies have developed techniques to estimate their risk from insuring a group of people by processing the protected health information about the group. Federal privacy laws, however, prevent the insurance companies from obtaining protected health information without individual authorizations from the each person in the group.

SUMMARY

[004] The systems and techniques described here relate to de-identifying medical history information.

[005] In one aspect, a computer-implemented method includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group.

[006] Implementations may include any of all of the following features. Producing information that characterizes the group may include producing a request token for each individual included in the group. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing information that characterizes the group may include comparing the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. Producing information that characterizes the group may includes determining if the comparison provides at least a minimum number of matches. Producing information that characterizes the group may include requesting a predefined portion of the information. Additionally, producing information that characterizes the group may include determining if the group includes at least a minimum number of individuals. The private data may represent medical related information associated with the individuals of the group.

[007] In another aspect a system includes an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group. The system may also include a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The data server is also configured to provide the produced information to report the characteristics of the group.

[008] Implementations may include any of all of the following features. The data server may provide a request token for each individual included in the group to produce the information that characterizes the group. The request token for each individual may represent encrypted data that identifies the corresponding individual. The data server may

be configured to compare the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. The data server may be configured to determine if the comparison provides at least a minimum number of matches. The request may represent a predefined portion of information to use for producing the information that characterizes the group. The encryption server may be configured to determine if the group includes at least a minimum number of individuals. The private data may represent medical related information associated with the individuals of the group.

[009] In another aspect, one or more computer readable media storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations that include producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The operations also include providing the produced information to report the characteristics of the group.

[010] Implementations may include any of all of the following features. Producing information that characterizes the group may include producing a request token for each individual included in the group. Producing such a request token for each individual may include encrypting respective data that identifies each individual. Producing information that characterizes the group may include comparing the request tokens to tokens associated with the information to be produced. The tokens associated with the information to be produced and the request tokens may be similarly encrypted. Producing information that characterizes the group may includes determining if the comparison provides at least a minimum number of matches. Producing information that characterizes the group may include requesting a predefined portion of the information. Additionally, producing information that characterizes the group may include determining if the group includes at least a minimum number of individuals. The private data may represent medical related information associated with the individuals of the group.

[011] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and

advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 illustrates exemplary circumstances in which protected health information is stored by healthcare providers, claims clearing houses, and other source sites, and requested by an insurer.

FIG. 2 illustrates an exemplary method and system that enables an insurer to obtain medical information about a group of people without violating the privacy of persons in the group.

FIG. 3 illustrates an exemplary system incorporating an encryption server and a de-identified data server to enable a user who is not permitted to obtain the private data of a group of people to instead obtain a report that characterizes the group as a whole.

FIG. 4 illustrates an exemplary message requesting de-identified data about a group of people.

FIG. 5 is a flowchart that represents exemplary operations of a token generator.

FIG. 6 is a flowchart that represents exemplary operations of a token matcher.

FIG. 7 represents a computer system and related components.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

[012] Referring to FIG. 1, when a doctor treats Jack 102 for high blood pressure, a surgeon removes Jack's gallstones, and a pharmacist fills Jack's prescription for insulin, Jack leaves a trail of electronic records 104 with healthcare professionals (e.g., healthcare profession 106), in their offices (e.g., doctor's office, nurse's station, etc.), in healthcare facilities (e.g., a hospital 108, a pharmacy 110, a nursing home, etc.) and the like. The electronic records 104 contain medical data 112 about Jack, for example his illnesses 114

and treatments 116. Each piece of medical data 112 is associated with personally identifiable information 118 that identifies Jack and distinguishes him from all other patients, such as his first name 120, last name 122, date of birth 124, gender 126, and zip code 128. Together, the pieces of medical data 112 and the personally identifiable information 118 make up Jack's protected health information (PHI) 130.

[013] Each of Jack's healthcare providers may submit health insurance claims 105 containing PHI 130, as well as additional PHI 130, to a claims clearing house 137. The claims clearing house 137 may store the PHI 130 of many patients 134, including Jack, in a PHI database 136. A de-identifier 142 can process the PHI 136 to generate irreversibly de-identified data 140 by removing all personally identifiable information 118 or otherwise transforming the PHI 130 so that it cannot be associated with a particular person. A claims warehouse 139 stores de-identified data 140 about many patients 134. Claims clearing houses 137 and claims warehouses 139 are optimized for retrieving and providing PHI 136 and de-identified data 140 for use in further processing, but health care providers such as healthcare professional 106 and pharmacies 110 may also serve as source sites 138 for de-identified data in a distributed system.

[014] By searching for Jack's personally identifiable information 118 in its electronic records 104, the pharmacy 110 is able to look up the various drugs in Jack's PHI 130 and, for example, check for bad interactions among them. Jack does not object to this use of his PHI 130 because it improves the quality of his healthcare. On the other hand, Jack would object to the pharmacy 110 giving his PHI 130 to third parties without his permission because that would disclose personal, private information about him that Jack's potential employers, for example, might use to discriminate against him.

[015] Federal laws, such as the Health Insurance Portability and Accountability Act (HIPAA), protect Jack by prohibiting the source sites 138 possessing Jack's PHI 130 from releasing it to third parties without Jack's permission. Under HIPAA, the source sites 138 can release only irreversibly de-identified data 140 without Jack's permission.

[016] A health insurer 150, for example, may be interested in the medical history information contained in Jack's PHI 130. Jack's employer 152 may like to buy a group

health insurance policy for the group 154 made up of Jack 102 and his coworkers 156. If the group 154 is too small, the insurance company 150 will not have the knowledge to fully understand the potential risk from future medical claims for the group 154 and need to set the rate to cover this unknown risk. In that case, the insurer 150 would like to use the PHI 136 from the group 154 to assess the risk of claims and set the group health insurance premium appropriately. Unfortunately, the group 154 may also be too large for the insurance company 150 to practically obtain permission from each person in the group, without which HIPAA prohibits the healthcare providers 138 from releasing the PHI 136 to the insurer 150. The de-identified data 140, which the healthcare providers or other source sites 138 could release without permission, is not useful to the insurer 150 because the insurer has no way to know whether it corresponds to the people in the group 154. With no way to obtain medical history data for the group, the insurer 150 cannot set the group insurance premium acceptably.

[017] Referring to FIG. 2, to provide the insurer 150 with the medical history information necessary to calculate the insurance premium for the group 154, without revealing the protected health information of persons in the group 154, the exemplary system 200 associates unique tokens 202 with the irreversibly de-identified data 140. The tokens 202 correspond to persons treated by healthcare providers but do not reveal the identities of the treated individuals. The insurer 150 can send a data request 203 to a third party 205, who in turn can generate request tokens 204, one for each person in the group 154. The third party 205 can send the request tokens 204 to a data aggregator 206. The data aggregator 206 stores de-identified data 140 and associated tokens 202. By searching for the request tokens 204 among the stored tokens 202, the data aggregator 206 can process the de-identified data to generate requested de-identified data 208 that corresponds to the group 154. A data processor 210 can process the requested de-identified data 208 to generate a report 212 containing metrics such as underwriting scores that are useful to the insurer 150 in assessing the overall risk of insuring the group 154.

[018] By using the tokens 202 and request tokens 204, no parties other than the authorized source sites 138 can associate de-identified data 140 with the identity of any person in the group of patients 134 or insureds (e.g., the group 154). The insurer 150

requesting the report 212 can never receive data associated with individuals. Further, the information in the report 212 may be processed into metrics that characterize a large group and cannot be used to infer information about individuals. De-identified data records may be provided to the data processor 210 (e.g., a third part data processor), but that third party may not have access to any personally identifiable information 118 about the group 154. Nor may any party with access to the de-identified data 140, other than the healthcare providers 138, also have access to the de-identifier 142. These features of the system 200 maintain the privacy of the protected health information 130.

[019] While we describe a system in which an insurer 150 needs to estimate the risk of insuring a group of potential customers, the system 200 can work for applications in which information characterizing a group needs to be generated from the private data of group members. In one arrangement, the system may implement Microsoft Windows-based computers in connection with internet-based components. However, other implementations may use other types of components that support the processing of medical history information from healthcare databases.

[020] Referring to FIG. 3, in an exemplary system 300, a user 302 specifies a group of people using identifying data for each group member. Referring briefly to FIG. 4, an exemplary set of identifying data 404 is illustrated. Returning to FIG. 3, the user may obtain the personally identifiable information from a database 304 by retrieving it in the form of a group file 330. The user 302 generates a request message, which may be a computer file, which uniquely identifies each member of the group using the identifying data 304. Typically, the group contains at least a minimum number of unique members. A request message 306 may be generated at a remote computer operated by the user 302.

[021] The request message 306 contains a set of identifying data 404 (see FIG. 4) for each group member, as well as data that identifies a user 402 (see FIG. 4), such as the user's name, email address, phone number and facsimile number, and a batch number that identifies the request. The group members' identifying data 404 (see FIG. 4) may include first name, last name, date of birth, gender, and zip code as well as other identifiers, such as social security number, that may be added to ensure that members are uniquely

identified. In some examples, fewer identifiers may be used. The request message 306 may also include optional indications that the user 302 requests a particular type of report 212 or requests additional processing to enhance the value of the report.

[022] The request message 306 is sent over a communications network 310 (e.g., the Internet, a LAN, etc.) to an encryption server 312. If the request message 306 contains a minimum number of group members, the encryption server 312 creates a unique token, or identifier, for each person in the message 306. The encryption server creates each token by applying a token generator 314 that encrypts the personally identifiable information of each group member. The set of tokens corresponding to all the group members constitutes a batch of request tokens 204. The minimum number of group members, for example ten, is chosen to make it effectively impossible to associate individual group members with individual tokens in the batch of request tokens 204.

[023] The encryption server 312 provides the request tokens 204 to the de-identified data server 318. The de-identified data server 318 stores records of de-identified data and corresponding tokens 320 obtained from source sites 138 such as pharmacies, healthcare professionals and electronic claims clearing houses. Each token obtained from the source sites 138 may have been created using the same token generator 314 used by the encryption server 312, or using any other means that generates the identical token for the same personally identifiable information.

[024] For example, a pharmacy tracks the prescription histories of the patients being served. De-identified prescription histories and corresponding tokens are sent to the de-identified data server 318. At the request of a user 302, such as an insurance company, the encryption server 312 generates tokens identical to the patients' tokens using the same personally identifiable information. A unique token corresponding to the same personally identifiable information permits the pharmacy and the insurance company to refer to the same anonymous people without the insurance company ever associating protected health information with a particular person. To produce tokens and request tokens, one or more encryption techniques may be utilized, for example, hash functions and other methodologies may be implemented.

[025] A token matcher 326, executed by the de-identified data server 318, performs a look-up in the de-identified database 320 to find all tokens in the database that match the tokens sent from the encryption server 312. All available data for matched tokens, the requested de-identified data 208, is retrieved for use in the report generator 328. The de-identified data may include, for example, prescription history, medical claims, and hospital claims. The de-identified data server 318, or the data processor 210 may use the report generator 328 to process the requested de-identified data 208 in a way that leaves it irreversibly de-identified. An example of such processing is an underwriting algorithm that transforms the data into an underwriting assessment. The report generator formats the processed data into an electronic or hardcopy report 212 that is returned to the user.

[026] While the report 212 is described as generated on a computer system, it may also be generated in part or entirely outside the computer system. For example, the report 212 could be conveyed to the user via regular mail or other similar technique. In particular, the report may be generated and printed at the site of the de-identified data server 318 and subsequently communicated to the user 302 without using the computer network. The report generator 328 may also reside in the data processor 210 separate from the de-identified data server 318.

[027] In one arrangement, once the relevant information and options have been selected, the user 302 submits the request by clicking a submit button. The request message 306 may be encrypted prior to being transmitted over a computer network 310. At the encryption server 312, the request message 306 is unencrypted and stored. The encryption server 312 may send an optional confirmation message to the user 302. The confirmation message may include the time and date that the message was received, and may indicate the service level and options selected by the user 302.

[028] Referring to FIG. 4, the user 302 can input the user's identifying information 402, including name, email address, phone number and/or facsimile number, in the first record, or set of fields, of the request message 306. The user can then input the personally identifiable information 404 for each of the group members, including first name, last name, gender, date of birth, and zip code. Equivalently, the user can incorporate the group

file 330 into the request message 306. Information about the insurance policy 408 for which the group has applied, or other insurance purpose for which the report 212 is being requested may also be included in the request message 306. The format of the request message 306 may be adjusted based on the user's 302 needs.

[029] The request message 306 may also include information about the level of service 410 requested by the user 302, for example the quantity, quality or type of information. A first level of service may request up to six months of medical history; a second level may request up to twelve months of history; and a third level may request a two year medical history. Alternatively, instead of providing the user 302 with a variety of service level options 410, the system 300 may simply retrieve all of the medical history information available for the group.

[030] The user 302 may also request additional, optional information 412. For example, the user 302 may request information regarding the drug categories and drug indications associated with the drugs in the de-identified data. Drug indications include the medical conditions associated with each drug. Drug categories include the type of drug. This data can be passed to the data processor 210 to include in the report 212. Alternatively, this data may be returned as part of every report 212.

[031] Referring to FIG. 5, a flowchart 500 represents a particular arrangement of operations of a token generator (e.g., the token generator 314 shown in FIG. 3). Operations include receiving 502 the request message (e.g., request message 306) containing the personally identifiable information of each person in the group (e.g., such as the group 154 shown in FIG. 1). Upon receiving the request message, operations may also include determining 504 whether the message includes the minimum number of persons. If the message does not include the minimum number of persons, the token generator returns to receive 502 a request message. A limit on the minimum number of persons ensures that a report (e.g., the report 212) covers enough people such that it is difficult (if not impossible) to infer any association between particular persons and the information in the report. If the message does include the minimum number of people, operations of the token generator include producing 508 tokens from the identifying data of each person.

Producing the tokens may include applying an encryption algorithm to the identifying data of each person. The tokens uniquely identify each person in the group 154.

[032] Operations also include determining 510 if the request message includes a batch number. If the message does not include a batch number, operations include generating 512 a batch number. Operations also include providing 516 the tokens, batch number and report options. The individual tokens are placed in a batch file and may be encrypted before being transmitted over the network.

[033] Each batch file of request tokens 204 also specifies the information needed for the report 212. The request tokens are transmitted to the de-identified data server 318, unencrypted and processed using rules for searching, matching, and retrieving healthcare data.

[034] Referring to FIG. 6, a flowchart 600 represents a particular arrangement of operations of a token matcher (e.g., the token matcher 326 shown in FIG. 3). Operations include receiving 602 request tokens (e.g., such as the request tokens 204 shown in FIG. 2). Operations may also include receiving 604 a token (e.g., such as the token 202) and associated de-identified data (e.g., such as the de-identified data 140), typically from source sites (e.g., such as the source site 138 shown in FIG. 1). Upon receiving a request token, de-identified data and a token, operations include determining 606 whether the request token matches the token. If no match is found, operations include returning to receive 604 more tokens and de-identified data. If a match is found, operations include processing 608 the de-identified data. Processing may include storage for later retrieval. In some arrangements, operations may also include determining whether a minimum number of matches has been detected. If such a minimum number of matches has not occurred in comparing the request tokens and the tokens, action may be taken (e.g., pause or restart processing) until the predefined number of matches has been detected (e.g., so as not to increase the probability of one or more individuals being identified by a process of elimination).

[035] The de-identified data (e.g., such as the de-identified data 140) may include a list of drugs prescribed over the requested period for the members of the group (e.g., such as

the group 154). The list of drugs prescribed may include the drug name, form, strength, days supplied, and date dispensed. As part of processing 608 the de-identified data, operations may include determining the drug category and drug indications for each drug prescribed. Operations may also include accessing a database relating the drug category and indications to each possible drug. The database may be maintained within the de-identified data server 318 database, or may be accessed on a remote server maintained by a third party.

[036] Upon processing the de-identified data, operations also include determining 610 if additional tokens remain in the batch of request tokens (e.g., such as the request tokens 204). If additional tokens remain, operations include receiving 602 more request tokens. If there are no additional request tokens, operations may include outputting 612 the processed, de-identified data.

[037] Operations may also include providing the number of tokens submitted, the number matched, and the overall match rate. The collected data covers the interval of historical data according to the level of service requested (e.g., as represented by the level of service 410 in FIG. 4). De-identified diagnosis and procedures data may also be included from administrative medical claims from a doctor's office (e.g., office 106) or a healthcare facility (e.g., the hospital 108).

[038] In addition to accessing and incorporating drug indication information for each drug prescribed to persons in the group (e.g., such as group 154), operations may include further processing of the requested de-identified data. For instance, operations may include determining the probability that a particular drug indicates a particular condition. In this example, in addition to providing the possible indications, the requested de-identified data would include the likelihood that anonymous individuals associated with the request tokens (e.g., such as request tokens 204) have each of the conditions indicated by the prescribed drugs. Operations may also include using expert rule systems to provide health status information based on the prescription drug history information. Alternatively, operations may include using diagnosis codes from medical claims data to assess health status.

[039] The requested de-identified data 208 may be sent for further processing to a third party data processor (e.g., data processor 210) who may apply proprietary algorithms, modify the data format, or generate additional reports, provided that no re-identifiable information is transmitted to the user 302. Third parties may not have access to the request message 306 and the group file 330 so that no association may be inferred between the de-identified data 140 and particular persons in the group 154.

[040] The report 212 provides the insurer 150 with information for making an immediate, informed decision about the insurance related risks. In particular, the insurer 150 may accept, reject or adjust the group's insurance rating depending on the information in the report 212. Actuarial tables and formulas may be used to determine which of the insurance actions are taken. The report 212 may be used alone to make decisions about the insurability of the group 154, or may simply indicate that additional investigation is needed.

[041] FIG. 7 is a schematic diagram of a generic computer system 700. The system 700 can be used for the operations described in association with any of the computer-implemented methods described previously, according to one implementation. The system 700 includes a processor 710, a memory 720, a storage device 730, and an input/output device 740. Each of the components 710, 720, 730, and 740 are interconnected using a system bus 750. The processor 710 is capable of processing instructions for execution within the system 700. In one implementation, the processor 710 is a single-threaded processor. In another implementation, the processor 710 is a multi-threaded processor. The processor 710 is capable of processing instructions stored in the memory 720 or on the storage device 730 to display graphical information for a user interface on the input/output device 740.

[042] The memory 720 stores information within the system 700. In some implementations, the memory 720 is a computer-readable medium. The memory 720 is a volatile memory unit in some implementations and is a non-volatile memory unit in other implementations.

[043] The storage device 730 is capable of providing mass storage for the system 700. In one implementation, the storage device 730 is a computer-readable medium. In various different implementations, the storage device 730 may be a floppy disk device, a hard disk device, an optical disk device, or a tape device.

[044] The input/output device 740 provides input/output operations for the system 700. In one implementation, the input/output device 740 includes a keyboard and/or pointing device. In another implementation, the input/output device 740 includes a display unit for displaying graphical user interfaces.

[045] The features described can be implemented in digital electronic circuitry, or in computer hardware, firmware, software, or in combinations of them. The apparatus can be implemented in a computer program product tangibly embodied in an information carrier, e.g., in a machine-readable storage device, for execution by a programmable processor; and method steps can be performed by a programmable processor executing a program of instructions to perform functions of the described implementations by operating on input data and generating output. The described features can be implemented advantageously in one or more computer programs that are executable on a programmable system including at least one programmable processor coupled to receive data and instructions from, and to transmit data and instructions to, a data storage system, at least one input device, and at least one output device. A computer program is a set of instructions that can be used, directly or indirectly, in a computer to perform a certain activity or bring about a certain result. A computer program can be written in any form of programming language, including compiled or interpreted languages, and it can be deployed in any form, including as a stand-alone program or as a module, component, subroutine, or other unit suitable for use in a computing environment.

[046] Suitable processors for the execution of a program of instructions include, by way of example, both general and special purpose microprocessors, and the sole processor or one of multiple processors of any kind of computer. Generally, a processor will receive instructions and data from a read-only memory or a random access memory or both. The essential elements of a computer are a processor for executing instructions and one or

more memories for storing instructions and data. Generally, a computer will also include, or be operatively coupled to communicate with, one or more mass storage devices for storing data files; such devices include magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and optical disks. Storage devices suitable for tangibly embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. The processor and the memory can be supplemented by, or incorporated in, ASICs (application-specific integrated circuits).

[047] To provide for interaction with a user, the features can be implemented on a computer having a display device such as a CRT (cathode ray tube) or LCD (liquid crystal display) monitor for displaying information to the user and a keyboard and a pointing device such as a mouse or a trackball by which the user can provide input to the computer.

[048] The features can be implemented in a computer system that includes a back-end component, such as a data server, or that includes a middleware component, such as an application server or an Internet server, or that includes a front-end component, such as a client computer having a graphical user interface or an Internet browser, or any combination of them. The components of the system can be connected by any form or medium of digital data communication such as a communication network. Examples of communication networks include, e.g., a LAN, a WAN, and the computers and networks forming the Internet.

[049] The computer system can include clients and servers. A client and server are generally remote from each other and typically interact through a network, such as the described one. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.

[050] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the following claims.

WHAT IS CLAIMED IS:

1. A computer-implemented method comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group.

2. The computer-implemented method of claim 1, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

3. The computer-implemented method of claim 2, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

4. The computer-implemented method of claim 2, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

5. The computer-implemented method of claim 4, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

6. The computer-implemented method of claim 4, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

7. The computer-implemented method of claim 1, in which producing information that characterizes the group includes requesting a predefined portion of the information.

8. The computer-implemented method of claim 1, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

9. The computer-implemented method of claim 1, in which the private data represents medical related information associated with the individuals of the group.

10. A system comprising:

an encryption server for producing a request token of each individual included in a group identified in a request for information that characterizes the group; and

a data server for producing the information that characterizes the group from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information, the data server is configured to provide the produced information to report the characteristics of the group.

11. The system of claim 10, in which the data server is provided a request token for each individual included in the group to produce the information that characterizes the group.

12. The system of claim 11, in which the request token for each individual represents encrypted data that identifies the corresponding individual.

13. The system of claim 11, in which the data server is configured to compare the request tokens to tokens associated with the information to be produced.

14. The system of claim 13, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

15. The system of claim 13, in which the data server is configured to determine if the comparison provides at least a minimum number of matches.

16. The system of claim 10, in which the request represents a predefined portion of information to use for producing the information that characterizes the group.

17. The system of claim 10, in which the encryption server is configured to determine if the group includes at least a minimum number of individuals.

18. The system of claim 10, in which the private data represents medical related information associated with the individuals of the group.

19. One or more computer readable media storing instructions that are executable by a processing device, and upon such execution cause the processing device to perform operations comprising:

producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals, wherein the identity of the individuals is unattainable from the produced information; and

providing the produced information to report the characteristics of the group.

20. The computer readable media of claim 19, in which producing information that characterizes the group includes producing a request token for each individual included in the group.

21. The computer readable media of claim 20, in which producing the request token for each individual includes encrypting respective data that identifies each individual.

22. The computer readable media of claim 20, in which producing information that characterizes the group includes comparing the request tokens to tokens associated with the information to be produced.

23. The computer readable media of claim 22, in which the tokens associated with the information to be produced and the request tokens are similarly encrypted.

24. The computer readable media of claim 22, in which producing information that characterizes the group includes determining if the comparison provides at least a minimum number of matches.

25. The computer readable media of claim 19, in which producing information that characterizes the group includes requesting a predefined portion of the information.

26. The computer readable media of claim 19, in which producing information that characterizes the group includes determining if the group includes at least a minimum number of individuals.

27. The computer readable media of claim 19, in which the private data represents medical related information associated with the individuals of the group.

ABSTRACT

A computer-implemented method includes producing information that characterizes a group of individuals from a set of private data representing characteristics of the individuals. The identity of the individuals is unattainable from the produced information. The method also includes providing the produced information to report the characteristics of the group.

22448586.doc

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled DE-IDENTIFYING MEDICAL HISTORY INFORMATION FOR MEDICAL UNDERWRITING, the specification of which:

[X] is attached hereto.
[ ] was filed on _____ as Application Serial No. _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. Serial No.	Filing Date	Status
61/222,428	July 1, 2009	Pending

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
			[] Yes [] No
			[] Yes [] No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

PTO Customer Number 26161

Combined Declaration and Power of Attorney

Direct all telephone calls to JEFFREY J. BARCLAY at telephone number (617) 542-5070.

Direct all correspondence to the following:

26161
PTO Customer Number

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: ANDREW L. PARISI

Inventor's Signature: _____ Date: 6/30/10

Residence Address: Victor, New York
Citizenship: United States
Post Office Address: 559 Fox Hunt Drive
Victor, New York 14564
United States

22446190.doc



100
Source Sites
138
Claims Clearing House
Claims Warehouse
137
139
136
140
De-identifier
Protected Health Information
142
De-identified Data
150
152
Insurer
Employer
156
102
Jack
154
105
105
105
claims
claims
claims
110
108
106
Pharmacy
Hospital
Healthcare Professional
104
114
116
120
122
124
126
128
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP
Illness, treatment, . . . , name1, name2, DOB, gender, ZIP
112
118
130
102
Jack
134

FIG. 1



200
138
214
202
140
Source Sites
token, de-identified data
token, de-identified data
token, . . .
. . .
154
Group of Insureds
Healthcare Professional
202
Tokens
140
De-identified data
206
Data Aggregator
204
205
203
150
Request Tokens
Third Party
Data Request
Insurer
Claims Clearing Houses
208
Requested de-identified data
Pharmacies
Data Processor
134
Report
210
212
Group of Patients

FIG. 2



Encryption Server
300
312
314
Token Generator
310
204
Request Tokens
306
Request Message
De-identified Data Server
318
326
302
User
Token Matcher
Report Generator
328
Report
330
212
320
Group File
304
De-identified Data and Tokens
Identifying Data
140
202
De-identified Data
Tokens
138
Source Sites

FIG. 3



306
REQUEST MESSAGE
402
user's name, user's email address, user's phone number, user's facsimile number, . . .
404
first name 1, last name 1, gender 1, date of birth 1, zip code 1, . . .
first name 2, last name 2, gender 2, date of birth 2, zip code 2, . . .
first name 3, last name 3, gender 3, date of birth 3, zip code 3, . . .
. . .
first name N, last name N, gender N, date of birth N, zip code N, . . .
406
batch number
408
type of insurance policy
410
level of service requested
412
optional report content requested

FIG. 4



500
502
Receive request message containing personally identifiable information
504
Minimum number of persons?
N
Y
508
Produce tokens from personally identifiable information
510
Does request message include batch number?
N
512
Generate batch number
Y
516
Provide tokens, batch number, and report options

FIG. 5



600
602
Receive request tokens
604
Receive tokens plus associated de-identified data
606
Tokens match?
N
Y
608
Process de-identified patient data
610
Additional token?
Y
N
612
Output processed, de-identified data

FIG. 6



700
Processor
710
720
Memory
750
Storage Device
730
Input/Output
740
Input/Output
Devices

FIG. 7

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris III
Filer:	Jeffrey J. Barclay/Paul Micele
Attorney Docket Number:	25412-0002001

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Utility filing Fee (Electronic filing)	4011	1	82	82
Utility Search Fee	2111	1	270	270
Utility Examination Fee	2311	1	110	110
Pages:				
Claims:				
Claims in excess of 20	2202	7	26	182
Miscellaneous-Filing:				
Petition:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
		Total in USD ($)		**644**

Electronic Acknowledgement Receipt

EFS ID:	7930323
Application Number:	12827745
International Application Number:	
Confirmation Number:	5602
Title of Invention:	De-identifying Medical History Information for Medical Underwriting
First Named Inventor/Applicant Name:	Andrew L. Paris III
Customer Number:	26161
Filer:	Jeffrey J. Barclay/Stacey Kelm
Filer Authorized By:	Jeffrey J. Barclay
Attorney Docket Number:	25412-0002001
Receipt Date:	30-JUN-2010
Filing Date:	
Time Stamp:	17:14:24
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$644
RAM confirmation Number	4781
Deposit Account	061050
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Exhibit 1002

1	Transmittal of New Application	2001pap.pdf	50152 bc6bc4b87cf46fe835ca8536070edc82d6aaac98	no	2
Warnings:					
Information:					
2	Nonpublication request from applicant.	2001nonpub.pdf	41684 e0752bb6fb3dedc7cf62591f0d8416fadc6be049	no	1
Warnings:					
Information:					
3		application.pdf	120613 a3690ba169b44c24ce8923636c089973eb1bcb2e	yes	19

Multipart Description/PDF files in .zip description

Document Description	Start	End
Specification	1	15
Claims	16	18
Abstract	19	19

Warnings:					
Information:					
4	Oath or Declaration filed	declaration.pdf	208634 ef7695166121d7c175dc58bd2f2aaa92343b98ed	no	2
Warnings:					
Information:					
5	Drawings-only black and white line drawings	figures.pdf	193159 4032db2c4a1d7d557f19effa623757307852cd78	no	7
Warnings:					
Information:					
6	Fee Worksheet (PTO-875)	fee-info.pdf	36263 9393c733aec10eba92b730d5216b2c995824766a	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	650505		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

SCORE Placeholder Sheet for IFW Content

Application Number: 12827745 Document Date: 6/30/2010

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

- Drawings – Other than Black and White Line Drawings

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

To access the documents in the SCORE database, refer to instructions developed by SIRA.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface.
- Other USPTO employees can bookmark the current SCORE URL (http://es/ScoreAccessWeb/).
- External customers may access SCORE content via the Public and Private PAIR interfaces.

Form Revision Date: February 8, 2006

Filing Date: 06/30/10

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 12/827,745

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE ($)	SMALL ENTITY FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY FEE ($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	82		N/A	
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	270		N/A	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	110		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	27 minus 20 =	7	x$26	182	OR	x$52	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	*	x$110			x$220	
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $270 ($135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR						
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))			195			390	
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	644		TOTAL	

APPLICATION AS AMENDED – PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE ($)	SMALL ENTITY ADDI-TIONAL FEE ($)	OR	OTHER THAN SMALL ENTITY RATE ($)	OTHER THAN SMALL ENTITY ADDI-TIONAL FEE ($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					N/A		OR	N/A	
						TOTAL ADD'T FEE		OR	TOTAL ADD'T FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDI-TIONAL FEE ($)	OR	RATE ($)	ADDI-TIONAL FEE ($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					N/A		OR	N/A	
						TOTAL ADD'T FEE		OR	TOTAL ADD'T FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.